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Terminology and Abbreviations 	  
ANS   Autonomic Nervous System 
B cells   B lymphocytes (WBC) that mostly mature into Effector B cells. 
Effector B cells Plasma cells (WBC) that produce Ig, including IgA.  
ELISA   Enzyme-Linked Immunosorbent Assay 
ES   Effect Size 
GALT   Gut Associated Lymphoid Tissue 
J-chain  A polypeptide that joins dimeric IgA together with the SP 
Ig   Immunoglobulin / Antibody 
IgA   Immunoglobulin A / Antibody A 
IgA1   Monomeric IgA that is mainly found in serum 
IgA2   Dimeric IgA that is mainly found in secretions 
LPT   Lymphatic Pump Technique, a subcategory of OMT 
MALT   Mucosa Associated Lymphoid Tissue 
OMT   Osteopathic Manipulative Treatment  
OU   Oral Ulceration 
pIgA   Polymeric Immunoglobulin A 
pIgR   Poly Ig Receptor, allows transcytosis of dimeric IgA across epithelium 
Sal SIgA  Salivary SIgA / Secretory IgA in Saliva  
SIgA   Secretory IgA (IgA1) 
T cells   T lymphocytes (WBC) that play a major role in cell-mediated immunity 
TLP   Thoracic Lymphatic Pump. Categorised under LPT 
URTI   Upper Respiratory Tract Infection 
WBC   White Blood Cells / Lymphocytes 
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1.0 Introduction 
Osteopathic healthcare is based on manual therapeutic attempts to help the body maintain 
and reestablish homeostasis and healing. This approach incorporates the broad 
understanding that unhindered flow of blood and lymphatic fluid is a prerequisite for human 
health. Osteopathic practitioners claim to locate and correct structural or functional changes 
in the tissues of the human body that may impair the free flow of blood and lymph 
(Degenhardt & Kuchera, 1996). Osteopaths have used osteopathic lymphatic pump 
techniques (LPT) as a treatment tool since the late nineteenth century (Still, 1899, 1902). 
Lymphatic Pump Techniques are rhythmic techniques that attempt, over certain areas of the 
lymphatic system such as the thorax, liver, spleen, abdomen and feet, to improve lymphatic 
flow locally as well as systemically. The osteopathic thoracic lymphatic pump (TLP) is a 
technique that is performed on the thorax and has been used by osteopaths claiming to 
improve lymphatic flow (Amalfatino, 1987; Chikly, 2005; Kuchera & Kuchera, 1994a, b; Ward, 
2003b). One possible consequence of these techniques is to increase immunoglobulin A 
(IgA) levels in secretions such as saliva and mucous membranes to protect the body against 
pathogens. People who have relatively decreased levels of salivary secretory IgA (Sal SIgA) 
commonly exhibit recurrent upper respiratory tract infection (URTI) and or oral ulceration 
(OU) (Benjamini, Coico, & Sunshine, 2000; Brandtzaeg, 2007; Hanson, Bjokander, & 
Oxelius, 1983; Paul, 2003). Two recent research studies (Ehrlenbach, 2011; Saggio, 
Docimo, Pilc, Norton, & Gilliar, 2011) suggest that Sal SIgA following TLP in a healthy study 
population may increase slightly over a short period of time. Ehrlenbach (2011) reported a 
short-term increase of Sal SIgA concentrations immediately post-TLP treatment in all eight 
participants and a short-term increase of Sal SIgA secretion rate immediately post-TLP 
treatment in 7 of 8 participants. The immediate post-treatment short-term increase of Sal 
SIgA secretion rate showed a large effect size (ES) of Cohen's d = 3.0 (p=0.03) with an 
average increase of 136%. Though not controlled, these data indicate a strong correlation 
between TLP and post-intervention increase of Sal SIgA secretion rate. Saggio, Docimo, 
Pilc, Norton, and Gilliar (2011) investigated the impact of Osteopathic Manipulative 
Treatment (OMT), consisting of a combination of three osteopathic techniques including TLP, 
on Sal SIgA levels by measuring Sal SIgA concentrations 60 minutes post-intervention in a 
stressed population (n=25). Participants were second-year osteopathic medical students at 
New York College of Osteopathic Medicine who were scheduled to take their national board 
examination (Comprehensive Osteopathic Medical Licensing Examination - USA Level 1) 
two to three weeks after their participation in the study. Osteopathic Manipulative Treatment 
resulted in a significant (F,5.92; p<0.025) increase (average increase of 139%) in post-
intervention Sal SIgA levels compared with the control group, who sat quietly and relaxed in 
a separate area for 20 minutes (average increase of 32%). 
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1.1 Aim  
The aim of this research thesis is to investigate the claims and theory behind osteopathic 
lymphatic pump techniques and a possible effect on immune health, in this case measured 
by changes in Sal SIgA. The thesis is presented in three sections, literature review, 
manuscript and appendices. The first section comprises a review of the literature surrounding 
the human immune system emphasising the physiology and salival secretion of 
immunoglobulin A, its links with health indicators, and the effect of osteopathy on immune 
function.  
 
The second section describes a study undertaken to establish to what extent the osteopathic 
TLP technique affects immediate and short-term Sal SIgA in a repeated case series of four 
adult males who report recurrent URTI and OU but are otherwise healthy. In order to improve 
the possibility of detecting any small changes that might occur following this technique, this 
population was targeted because of the likelihood of a suppressed mucosal immune system. 
Another aim was to observe whether this population displayed levels of salivary SIgA below 
the normal reference range.   
 
Ethics documentation, research questionnaires and additional data not reported in the 
manuscript are presented in the third section.	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2.0 Overview of the Human Immune System 
Our environment contains numerous microorganisms that can cause disease in the human 
body. The human immune system is a complex system that is concerned with the defence of 
the host, primarily against the threat of disease caused by infectious organisms, termed 
pathogens. Immunity essentially refers to all mechanisms used by the body as protection 
against environmental agents that are foreign to the body and it may be innate or acquired.  
 
2.1 Innate Immunity 
Innate immunity describes pre-existing mechanisms and elements that are designed to 
prevent infection by pathogens or to mount an immediate defence against the infectious 
agent. There are physical, chemical and biochemical barriers with which an individual is 
born, including body surfaces and internal components, such as skin, mucous membranes, 
the cough reflex, and particular immune cells (Benjamini et al., 2000). These elements 
present effective barriers to environmental agents and are always present to protect the body 
from challenges by foreign invaders. They are called innate because they are present before 
infection, although the amount of some components may increase following infection (Wood, 
2006).  
 
2.2 Aquired Immunity 
Acquired immunity, also known as the adaptive immune system, is a more specialised form 
of immunity. It supplements the protection provided by innate immunity and is acquired by 
the initial contact with the invader, also termed antigen, triggering a chain of events that 
leads to activation of certain cells. When pathogens enter the human body, antibodies, also 
called immunoglobulins (Ig), recognise the specific antigens and trigger the immune system 
to produce antibodies specific to that antigen. The basic antibody molecule is depicted as a 
Y-shaped structure consisting of four protein subunits, two longer identical subunits called 
heavy chains linked to each other, which are linked to two shorter identical subunits called 
light chains, by disulphide bridges (Wood, 2006). Antibodies are divided into five major 
classes, IgA, IgD, IgE, IgG, and IgM, each of which has several unique biological properties. 
All antibodies have common structural features, which enable them to recognise and bind 
specifically to a unique structural entity on an antigen and perform a common biological 
function after combining with the antigen. Acquired immunity can be induced against 
thousands of natural and synthetic compounds.  
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There are two major types of cells that participate in acquired immunity. B lymphocytes or B 
cells, named after their origin in the bone marrow and T lymphocytes or T cells, named for 
their differentiation in the thymus. Both B cells and T cells are responsible for their specificity 
exhibited by the acquired immune response. B cells synthesise and secrete 
immunoglobulins, with specificity against the antigen, into the bloodstream. This process is 
termed antibody-mediated or humoral immunity (Benjamini et al., 2000). T cells, which also 
exhibit specificity against the antigen, by virtue of their T cell receptors, do not make 
antibodies but perform various effector functions when antigen-presenting cells come into 
contact with them within secondary lymphoid organs. Unlike B cells, each T cell, bearing 
many identical antigen receptors, circulates directly to the site of the antigen and performs its 
function when interacting directly with it. This process is termed cell-mediated immunity 
(Benjamini et al., 2000).  
 
Lymphocyte maturation, differentiation and proliferation all take place in the lymphatic 
organs. The primary (central) lymphatic organs, such as the thymus and the bone marrow, 
are those in which the maturation of T cells and B cells into antigen-recognising lymphocytes 
occurs. From there, mature B and T cells migrate through the bloodstream to the secondary 
(peripheral) lymphatic organs, where the antigen-driven proliferation and differentiation take 
place (Benjamini et al., 2000). Secondary lymphatic organs include mainly the mucosa-
associated lymphoid tissue (MALT), particularly the Peyer's patches of the terminal ileum as 
well as other parts of gut-associated lymphoid tissue (GALT), such as the numerous isolated 
lymphoid follicles and the appendix. Other sites include the lymph nodes, the spleen and the 
tonsils (Brandtzaeg, 2007). 
 
2.3 Immunoglobulin A 	  
Immunoglobulin A (IgA) is the predominant antibody in mucosal secretions and acts with 
innate mucosal defences to provide the first line of defence against pathogens and antigens 
presented at the mucosa. Reduced secretion of IgA may indicate immunosuppression 
(Gleeson & Pyne, 2000; Gleeson et al., 1999; Gleeson, Pyne, & Callister, 2003; Hagewald, 
Bernimoulin, Kottgen, & Kage, 2002; Moreira, Delgado, Moreira, & Haahtela, 2009; Neville, 
Gleeson, & Folland, 2008; Pyne et al., 2000; Teeuw, Bosch, Enno, Veerman, & Amerongen, 
2004); IgA levels and secretion rate are linked with health indicators (Chikly, 2005; Hanson et 
al., 1983; Rossen, Butler, & Waldman, 1970). This section provides an overview of IgA 
physiology, including structure, production, secretion, induction and regulation; diagnosis and 
monitoring of IgA; as well as consequences of deficiency and its relation to health.  
In the human body IgA is present as serum IgA and as secretory IgA (SIgA), the latter of 
which can be found as the main antibody in various external secretions such as saliva (Sal 
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SIgA), mucus in the intestinal and respiratory tracts, gastric fluid, sweat and breast milk. Two 
IgA heavy constant region (Cα) genes are present, giving rise to two IgA subclasses 
(Snoeck, Peters, & Cox, 2005, Wood, 2006). Immunoglobulin A1 is monomeric (basic Ig 
structure of one four-chain unit), and is the main constituent of IgA found in serum. 
Monomeric IgA is produced by B cells in the bone marrow as well as in some lymphoid 
organs. IgA2 is mainly found in mucosal secretions and has a dimeric form consisting of two 
Ig molecules (two four-chain units) joined by an additional polypeptide termed 'J-chain' and 
an additional protein called the secretory piece (Paul, 2003; Wood, 2006). Immunoglobulin 
A1 and A2 appear to have the same functions (Wood, 2006). 
 
2.3.1 Immunoglobulin A Production, Synthesis and Secretion 
The IgA and J-chain are produced by T cell dependent B cells in organized germinal centres 
of MALT such as Peyer's patches. The high prevalence of SIgA on mucosal surfaces is a 
result of cooperation between polymeric IgA (pIgA) producing plasma cells and mucosal 
epithelial cells that express an immunoglobulin receptor called polymeric Ig receptor (pIgR). 
After pIgA is released by nearby activated plasma cells, it diffuses through the stroma and 
binds to pIgR. The receptor-mediated transcytosis of dimeric IgA across the epithelium is 
shown in Figure 1. This process results in transportation of IgA across mucosal epithelial 
cells and its cleavage from pIgR for release into external secretions as SIgA, while the 
transcytosis helps to protect the IgA from breakdown by proteolytic enzymes that are found 
in secretions (Benjamini et al., 2000; Snoeck et al., 2005; Wood, 2006). Thus SIgA can 
survive in the gastrointestinal tract and provide protection against microbes that multiply in 
body secretions (Wood, 2006). SIgA is of importance in the primary immunological defence 
against local infections and its protective effect is thought to be due to its ability to prevent 
the invading organism from attaching, replicating and penetrating the epithelial surface 
(Benjamini et al., 2000; Latiff & Kerr, 2007; Wood, 2006).  
 	  
 
 
 
 
 
 
 
Figure 1: Secretion of dimeric IgA and receptor mediated transcytosis across the epithelium (Wood, 2006).	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2.3.2 Immunoglobulin A Deficiency 
Disorders in the development and differentiation of T cells, B cells (and antibody), synthesis 
of their products or interactions between them may lead to immune deficiencies that range in 
clinical severity from mild to fatal (Benjamini et al., 2000). Immune deficiencies are divided 
into two major categories: primary, which may be hereditary or acquired, in which the 
deficiency is the cause of the disease; and secondary, in which the immune deficiency is a 
result of other diseases, infection, drugs, age or malnutrition (Benjamini et al., 2000). Primary 
immune deficiencies are mainly inherited, can be very mild to severe and are categorised 
based on clinical presentation, roughly corresponding to the arm of the immune system 
malfunctioning (Wood, 2006).  
 
Patients with IgA deficiency either have a complete absence, termed selective IgA 
deficiency, or present with significantly low serum levels of IgA, partial IgA deficiency. 
Selective IgA deficiency is defined as an undetectable serum IgA level at a value ≤5mg/dL 
(≤0.05 g/L). Partial IgA deficiency refers to detectable but decreased IgA serum levels that 
are more than 2 standard deviations below age-adjusted means (Cochino, Popescu, & 
Gherghina, 2011; Latiff & Kerr, 2007). The most common primary immunoglobulin deficiency 
is selective IgA deficiency with an incidence of approximately 1 in 500 in the Western World 
(Benjamini et al., 2000; Latiff & Kerr, 2007). Although selective IgA deficiency can be primary 
(i.e. genetically determined) or secondary (due to the effects of drugs or diseases), primary 
IgA deficiency appears to be the most common (Latiff & Kerr, 2007). Latiff and Kerr (2007) 
report that partial IgA deficiency is a relatively common finding in laboratories that routinely 
measure immunoglobulins with approximately 1 in 35 samples tested as IgA deficient 
(IgA<0.06 g/L; adult reference range 0.8-4.0 g/L) and approximately 1 in 100 tested as 
selective IgA deficient. Primary IgA deficiency appears to be associated with decreased 
release of IgA by B cells due to a defect of terminal lymphocyte differentiation (Latiff & Kerr, 
2007).  
 
Many diseases have been reported in association with IgA deficiency, particularly 
autoimmune diseases (Latiff & Kerr, 2007). The most common association is with coeliac 
disease (Latiff & Kerr, 2007). There is an established association between coeliac disease 
and oral ulceration, commonly caused by recurrent aphthous stomatitis (Field & Allan, 2003). 
IgA deficient patients with symptoms predominantly suffer from recurrent OU (Field & Allan, 
2003; Porter & Scully, 1993), gastrointestinal and sinopulmonary infections, particularly URTI 
(Brandtzaeg, 2007; Cochino et al., 2011; Hanson et al., 1983; Latiff & Kerr, 2007; Paul, 
2003).  
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2.4 Secretory Immunoglobulin A in Saliva 
As an early line of defence in the oral cavity, Salivary Secretory Immunoglobulin A has the 
same function as SIgA in other parts of the body. Salivary SIgA can specifically neutralise 
enzymes, toxins and viruses and Sal SIgA inhibits the adherence of bacteria to oral surfaces 
to prevent bacterial penetration of the mucosa. It neutralises viruses by inhibiting the viral 
stages of fusion, attachment, internalisation and replication (Benjamini et al., 2000; Wood, 
2006).  
 
2.4.1 Induction and Regulation of Salivary Secretory Immunoglobulin A  
Induction and regulation of Sal SIgA is complicated. The local response involves the 
proliferation and differentiation of lymphoid cells into SIgA-producing B cells in the 
submandibular, sublingual and parotid salivary glands. The second response, referred to as 
the common mucosal system, involves the movement of antigen-activated T cells from MALT 
via the lymphatic system to the salivary glands where, upon entering the glandular tissue, the 
B cells mature under the influence of local T cells into SIgA-producing plasma cells (Teeuw 
et al., 2004). Both processes underlie neuro-endocrine influences governed by the 
autonomic nervous system (ANS) and the hypothalamic-pituitary-adrenal axis where the 
adrenal medulla, acted upon by sympathetic neurons, presents as a specialised part of the 
ANS. Activation of these pathways results in elevated levels of cortisol and catecholamines 
(epinephrine, norepinephrine), both able to bind with hormone receptors on immune cells 
(Bennet-Herbert & Cohen, 1993). This sympathetic stimulation not only regulates the 
induction and regulation but simultaneously regulates distant immune cells located in 
lymphoid tissue such as MALT, influencing antigen presentation, cell migration and antibody 
production (Elenkov, Wilder, Chrousos, & Vizi, 2000) and may also affect migration of IgA-
secreting B cells by vasoconstriction of blood vessels (Mackinnon, 1999). The increased 
SIgA production that occurs with moderate exercise, a sympathetic stimulus, cannot be 
dampened by blocking alpha- or beta-adrenergic receptors (Ring et al., 2000). This finding 
implies mechanisms of sympathetic nervous system action that are not mediated through 
classical receptor pathways. Further evidence suggests synergistic actions of sympathetic 
and parasympathetic stimuli. Proctor and Carpenter (2007) demonstrated that both 
sympathetic and parasympathetic stimuli of salivary glands in rats increased salivary 
secretion of SIgA and appeared to be regulated through transcytosis of the epithelial pIgR-
containing vesicles. Proctor, Carpenter, and Garrett (2000) showed that one week of 
sympathectomy in rats reduced parasympathetically-mediated secretion of SIgA, a non-
storage product mediated by pIgR, and this appeared to be related to decreased routing of 
pIgR to the basolateral membranes of epithelial cells. The same study showed that one week 
of pre-ganglionic sympathectomy and parasympathetic nerve stimulation in rats increased 
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stored protein secretion but not IgA secretion into saliva. These findings underline that neural 
control of SIgA synthesis, secretion and saliva production is synergistically influenced by 
both parts of the ANS (Guyton & Hall, 2000; Teeuw et al., 2004).   
 
2.4.2 Measurement of Secretory Immunoglobulin A in Saliva 
Saliva analysis is presently used in the diagnosis of hereditary disorders, such as immune 
deficiencies, autoimmune disease, endocrine, infectious and malignant diseases as well as 
for monitoring drug abuse. Saliva collection is a non-invasive, pain free, simple, cost-effective 
method for testing large populations. Moreover, individuals without any specialised training 
can obtain samples. Whole saliva is produced by the three major salivary glands (parotid, 
submandibular and sublingual gland) and by the minor salivary glands that are present 
throughout the mouth. The collection of gland specific saliva is possible, however most 
routine studies collect whole saliva that is either stimulated via spitting or the use of citric 
acid, or non-stimulated by passive drooling (Mahvash & Satish, 2008). Saliva collection via 
spitting and drooling may prove to be problematic for reasons of social barriers, particularly in 
elderly individuals and the use of citric acid can interfere with immunoassay analysis as it 
decreases the pH of saliva (Groeschl, 2008). Commercially available collection devices, such 
as absorbent collection pads are recommended to avoid cross contamination between 
subjects, however, they have been shown to absorb target molecules leading to falsely 
decreased measurement results (Groeschl, 2008).  
 
Immunoglobulin in secretions is most commonly measured by immunoassays that employ 
linking molecules labelled with reagents to detect antibodies or antigen. Immunoassays are 
economical in the use of reagents and very sensitive to the detection of antibodies (Roit, 
Brostoff, & Male, 2001). The enzyme-linked immunosorbent assay (ELISA) utilises an 
enzyme-linked antibody, bound to a solid support, such as a microtitre plate, that recognises 
and binds to the immunoglobulin of interest. Following periods of incubation and rinsing off 
any unbound immunoglobulin, a substrate that activates the enzyme is added. Bound 
antibody is quantified by the colour change of the activated enzyme (Mackinnon, 1999). The 
secretion rate is suggestive of absolute SIgA produced each minute indicating the availability 
of SIgA on the mucosal surfaces (Mackinnon, 1999). The salivary flow rate is determined by 
weighing and timing saliva samples and dividing the amount of saliva sample (ml) by the time 
required to collect the sample (min) (Salimetrics, 2009b). In general it is recommended that 
both the absolute concentration and secretion rate of Sal SIgA are reported (Akimoto et al., 
2003; Brandtzaeg, 2007; Groer et al., 1994; Groeschl, 2008; Kaufman & Lamster, 2002; 
Salimetrics, 2009b). 
 
	   17	  
2.4.3 Variability of Secretory IgA in Saliva 
Salimetrics (2009a) define normal salivary SIgA concentrations in healthy adults ranging 
from about 79 µg/ml to about 679 µg/ml. Jafarzadeh et al. (2008), define normal Sal SIgA 
levels in healthy individuals as above about 43 µg/ml at age 1-10 years, about 82 µg/ml at 
age 11-20, about 94 µg/ml at age 21-30, about 98 µg/ml at age 31-40, about 106 µg/ml at 
age 41-50, reaching a peak of about 113 µg/ml at age 51-60 and significantly decreasing to 
about 93 at age 61-70. Even though Sal SIgA is a popular choice of mucosal immune marker 
for research studies, due to its cost-effectiveness and ease of measurement, it is difficult to 
standardize quantifications of salivary SIgA due to many methodological problems with 
sample collection, processing and storage, even for studies performed by the same 
laboratory (Brandtzaeg, 2007). Salivary SIgA levels vary between studies depending on the 
methodology of saliva collection, for example the choice of salivary gland and type of 
collection device, or the type of test, for example single radial immunodiffusion or ELISA.  
Differences in SIgA levels in the saliva from different glands have been observed, with the 
highest levels found in the minor salivary glands (Brandtzaeg, 2007; Crawford, Taubman, & 
Smith, 1975). It is important to be aware of the impact of salivary flow rate on salivary SIgA 
concentration, which may partly explain differences among studies (Brandtzaeg, 2007). 
 
2.4.4 Influences on Salivary Secretory Immunoglobulin A  
There are several possible influences on Sal SIgA, incuding age, circadian effects, diet, 
exercise, smoking, stress and chewing. Sal SIgA exhibits age-related changes and begins to 
decrease during the lifetime of individuals, with an average onset age of over 60 years 
(Jafarzadeh et al., 2008). It also shows diurnal rhythm, decreasing from the highest levels in 
morning to the lowest in the evening (Hucklebridge, Clow, & Evans, 1998; Li & Gleeson, 
2004). Dimitriou, Sharp, & Doherty (2002) suggest a significant circadian variation in Sal 
SIgA concentration (18.69% decrease from am to pm), saliva flow rate (48.39% increase am 
to pm) and secretion rate (32.11% increase am to pm) in well trained swimmers. There is 
evidence that levels of Sal SIgA can be additionally influenced by everyday activities 
including diet (Albers et al., 2005; Bishop & Gleeson, 2009; Gleeson, Bishop, Oliveira, & 
Tauler, 2011; Gleeson, Nieman, & Pedersen, 2004; Hao, Dong, Huang, & Wu, 2011), 
exercise (Bishop & Gleeson, 2009; Gleeson & Pyne, 2000; Gleeson et al., 1995, 2003; 
Klentrou et al., 2002; Nieman, 1994, 2000) and stress levels (Bennet-Herbert & Cohen, 
1993; Jemmot & McClelland, 1989; Volkmann & Weekes, 2006). In general diet, along with 
age, is one of the major exogenous factors modulating individual immunocompetence 
(Albers et al., 2005) and dietary deficiencies of protein and micronutrients such as iron, zinc 
and vitamins A, E, B6 and B12 are associated with immune dysfunction (Gleeson et al., 
2004). Gleeson, Bishop, Oliveira, and Tauler (2011) showed a clinically and statistically 
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significant increase, with a large ES of 5.6 (p=0.03) in Sal SIgA secretion after 8 and 16 
weeks of probiotic supplementation versus placebo in highly active winter athletes. A review 
by Gleeson, Pyne, and Callister (2003) notes that regular moderate intensity exercise can 
have a positive long-term effect on Sal SIgA concentrations, irrespective of age or fitness 
level, with studies showing 15-57% increases in IgA concentrations from pre- to post-
exercise. In contrast to the increases in IgA with moderate exercise, exercise at high 
intensities results in immediate and longer-term (1 – 4 hours) 20 – 60% decreases in Sal 
SIgA concentration, with a full recovery of Sal SIgA concentrations by 24 hours after 
exhaustive exercise (Gleeson et al., 2003; Moreira et al., 2009). Smokers are observed to 
have elevated Sal SIgA levels, which have been interpreted as a reflection of oral mucosal 
protection (Norhagen & Engstrom, 1998). Opposingly, passive smoking in young children of 
both sexes has shown to decrease Sal SIgA levels (Avsar, Darka, Bodrumlu, & Bek, 2009). 
As for exercise and smoking, the effect of stress on IgA levels is not clear cut. Acute 
psychological stress has been shown to enhance Sal IgA levels (Allgrove, Gomes, Hough, & 
Gleeson, 2008), whereas chronic stress has been found to suppress Sal SIgA (Jemmot & 
McClelland, 1989; Volkmann & Weekes, 2006). Finally, research has shown that chewing 
stimulates epithelial cell transcytosis of IgA and increases secretion of SIgA into saliva 
(Proctor & Carpenter, 2001). Therefore, chewing is commonly used to stimulate saliva fluid 
volume and consistent instructions regarding chewing need to be delivered to participants 
prior to saliva sample collection (Brandtzaeg, 2007).  	  
2.5 Salivary Secretory Immunoglobulin A and its Relation to Health 
The complexity of the immune system with its numerous specific and important components 
makes it impossible to recognise one specific marker for immune health but individual 
markers are commonly used to reflect the function of a specific component of the immune 
system. As described earlier, IgA is commonly used as an immune marker for mucosal 
immunity (Brandtzaeg, 2007; Saluja, Kale, & Hallikerimath, 2012), as it exhibits an important 
protective function against pathogens. This raises the question about the extent that Sal 
SIgA levels indicate or affect health. 
 
Numerous studies have attempted to link decreased Sal SIgA concentrations to a variety of 
oral as well as systemic diseases, including the relationship of low Sal SIgA levels to dental 
caries, periodontal disease, mucous membrane diseases, chronic sialadenitis, Sjögren's 
disease, non-Hodgkin's malignant B cell lymphoma, celiac disease, human 
immunodeficiency virus (HIV) infection and AIDS (Benjamini et al., 2000; Brandtzaeg, 2007; 
Hanson et al., 1983; Paul, 2003). Reviews of such reports have been published but the 
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relation between low Sal SIgA levels and the above-mentioned diseases remains unclear 
(Brandtzaeg, 2007). There are several important variables influencing the levels of total IgA 
and other specific antibodies in oral secretions. These include difficulties with reproducibility 
and standardization of immunoassays, protein loss during sample handling and impact of 
flow rate (Brandtzaeg, 2007). In addition, a number of biological phenomena induced by 
mucosal antigen exposure are poorly defined in experimental animals and still more obscure 
in humans. Salivary SIgA is also believed to play a, still poorly understood, role in 
maintenance and return to local homeostasis as well as in modulation and education of the 
mucosal immunity of the intestines and airways (Teeuw et al., 2004).	  
 
In addition to its association with specific conditions, a number of lines of evidence support 
the view that there is an association between Sal SIgA and general immune health (Chikly, 
2005; Hanson et al., 1983; Rossen et al., 1970). For example, Volkmann and Weekes (2006) 
investigated the relationship between stress and health in young adults (n=34) identified by 
stress and health inventories and alterations in Sal SIgA and Sal cortisol concentration 
during a baseline (low-stress) session and during an examination (high-stress) session. 
Similarly, low basal SIgA and high basal cortisol has been linked with increased infection 
rates. Markova and Chuvirov (2007) report that  94% of 270 2 – 15 year old frequently ill 
children with monthly acute respiratory disease and combined pathology of the upper airway 
show low levels of Sal SIgA. Information about the selection of participants and their 
demographics is not available. The childrens’ low IgA levels could be related to factors other 
than frequent illness. For example, the selection of children may have been biased towards 
those with lower socio-economic status. Selection of participants from lower socio-economic 
status might have resulted in a large number of participants exposed to cold or damp 
housing or exposure to passive smoke, which could both have contributed to suppressed IgA 
levels. Therefore, it is difficult to assess the importance of infection in its influence of IgA 
levels. 
 
Salivary SIgA has been shown to be a useful diagnostic marker for monitoring exercise-
induced mucosal immunosuppression in high-performance athletes (Gleeson & Pyne, 2000; 
Gleeson et al., 1999; Pyne et al., 2000). For instance, several studies associate exercised-
induced low levels of Sal SIgA with an increased incidence of URTI in elite athletes 
(Gleeson, & Pyne, 2000; Gleeson et al., 1999, 2003; Hagewald et al., 2002; Hanson et al., 
1983; Klentrou et al., 2002; Moreira et al., 2009; Neville et al., 2008; Nieman, 1994; Pyne et 
al., 2000; Teeuw et al., 2004). Neville, Gleeson, and Folland (2008) examined the 
relationship between Sal SIgA and URTI in a cohort of elite professional yacht racing athletes 
(n=38) in the United States over 50 weeks of training by collecting weekly unstimulated 
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saliva samples at rest (38 hours post-exercise, consistent time of day) together with clinically 
confirmed URTI, training load and perceived fatigue rating. On a group basis, a significant 
28%, reduction in Sal SIgA occurred during 3-week pre-URTI episodes (p<0.005), and 
returned to baseline by 2 weeks after a URTI. A reduction in Sal SIgA of more than 40% of 
an athlete’s mean healthy Sal SIgA concentration indicated a one in two chance of 
contracting an URTI within 3 weeks when an athlete did not have or was not recovering from 
URTI. Typical decline in an individual's relative Sal SIgA concentration over the 3 weeks pre-
URTI appears to predict URTI risk, with a magnitude of the decrease related to the risk of 
URTI, independent of the absolute SIgA concentration (Neville et al., 2008).  
 
Salivary SIgA has also been used to monitor responses to acute psychological stressors. 
Acute stress results in elevated Sal SIgA levels, in contrast to chronic stressors which induce 
Sal SIgA suppression. In an attempt to investigate the effect of increased Sal SIgA on URTI, 
Kostinov, Suloeva, Tarasova, and Lukushkina (2006) evaluated the influence of bacterial 
lysate on the mucosal immunity of HIV infected children. This lysate, a topical immuno-
modulator, increased the synthesis of Sal SIgA in correlation with decreased inflammatory 
changes in the nasopharyngeal mucosa of the children (Kostinov, Suloeva, Tarasova, & 
Lukushkina, 2006).  
 
There is also good evidence that Sal SIgA has a protective role against the development of 
allergy (Böttcher, Häggström, Björgstén, & Jenmalm, 2002). Additionally, in vitro and in vivo 
research indicate that Sal SIgA can inhibit the adherence of bacteria to oral tissues and 
thereby protect against the development of gingivitis and caries (Teeuw et al., 2004). 
However, epidemiological research investigating the relationship between Sal SIgA and 
dental caries has produced conflicting data and inconsistencies are believed to relate to the 
fact that some species of bacteria can render Sal SIgA ineffective (Lamm, 1997). For 
instance, decreased levels of Sal SIgA are associated with dental caries, however studies 
that show significantly higher levels of Sal SIgA in children with caries hypothesise that 
increased levels of Sal SIgA may reflect a past exposure of the host to cariogenic 
microorganisms (Thaweboon, Thaweboon, Nakornchai, & Jitmaitree, 2008).  
 
For the most part, studies support the view that increased IgA levels have a positive impact 
on health, while decreased IgA concentrations are frequently associated with oral as well as 
systemic diseases. The potential role of manual therapies, in particular osteopathy, in 
modifying Sal SIgA levels, and therefore perhaps improving human immune health, by 
assisting lymphatic drainage is still unknown.   	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3.0 Osteopathy and Immune Health 
Osteopathic healthcare is a form of drug-free, non-invasive manual therapy attempting to 
help the body maintain and reestablish homeostasis and healing. This part of the literature 
review provides a short overview on the field of osteopathy and commonly utilised 
techniques for immune stimulation. Further, the features of osteopathic lymphatic pump 
techniques are discussed, with focus on the thoracic lymphatic pump, to understand how and 
to what extent TLP might influence Sal SIgA levels.  
 
In New Zealand osteopaths do not work as fully licensed physicians and modern osteopathy 
appears to have its scope of practice primarily specialised to the treatment of neuro-
musculoskeletal problems (OCNZ, 2013). Yet in the early days of the profession osteopathic 
practitioners were asked to treat numerous infectious diseases and were also utilised as 
primary health providers with full medical practice rights (Kuchera and Kuchera, 1994a; Still, 
1899, 1902; Ward, 2003). Osteopathic practitioners seek to optimise structures that are 
considered to be directly or indirectly related to immune function. Organs such as liver, 
thymus, spleen and the intestines, play an important role in the synthesis, neutralisation and 
elimination of immune related cells and are treated by osteopaths who claim that this 
treatment can improve their function either directly or by releasing restricted tissues 
surrounding the respective organ (Ward, 2003; Wood, 2006). Structures related to lymphatic 
flow such as lymph vessels and lymph nodes are not easily accessible by manually-applied 
hand contact and the osteopathic approach is centred on treating restrictions, a resistance or 
impedement to movement, in surrounding connective tissue, such as muscles and fascia 
(myofascia), through which those structures pass (Paoletti, 2006; Ward, 2003). Fascia is 
connective tissue that surrounds and connects internal structures throughout the body.  
 
Therefore, distorted function of myofascia is believed to hinder the movement of lymphatic 
fluid (Degenhardt & Kuchera, 1996; Kuchera & Kuchera, 1994a; Paoletti, 2006). Decreased 
lymphatic flow causes tissue accumulation of waste products and can interfere with cellular 
activity resulting in cell dysfunction and disease (Degenhardt & Kuchera, 1996). Increasing 
lymph flow and drainage of lymph fluid out of tissues optimises the filtering of fluid and the 
transport and removal of inflammatory mediators from sites of dysfunction (Degenhardt & 
Kuchera, 1996; Ward, 2003). Additionally, osteopathic treatment utilises a wide range of 
pumping and draining techniques.  	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3.1 Lymphatic Pump Techniques  
Lymphatic flow relies on the production of pressure gradients between abdominal and 
thoracic regions, produced by the action of the abdominal diaphragm to direct lymph through 
the thoracic duct towards the vena subclavia and inferior vena cava. Osteopathic medicine 
emerged as the first system of healthcare to develop specific manual techniques related to 
the lymphatic system (Chikly, 2005). Today, osteopaths use Osteopathic Manipulative 
Treatment (OMT) techniques for lymphatic stimulation, in particular a group of manipulations 
knowns as Lymphatic Pump Techniques (LPTs) which are designed to augment abdominal-
thoracic pressure gradients that develop during normal respiration (Ward, 2003). Some 
techniques are claimed to influence negative intrathoracic pressure of the thorax, while 
others are said to increase abdominal pressure. Techniques can be rhythmic or continuous 
and LPTs include the thoracic lymphatic pump, the liver, splenic, pancreatic, abdominal and 
pedal pumps and pectoral traction. The increased lymph flow that is believed to occur from 
these treatments is thought to accelerate removal of cellular waste, toxins, and bacteria from 
the interstitial fluid and also reduce oedema (Ward, 2003). 
 
3.2 Thoracic Lymphatic Pump Techniques  
TLP techniques are designed to affect the intrathoracic pressure gradients that are thought to 
augment thoracic range of motion and expiratory efficacy, while at the same time affecting 
lymphatic flow through the thoracic duct, rib cage mobility and associated ANS centres of 
sympathetic ganglions which take part in the autonomic regulation of salivary glands and 
intrathoracic organs (Kuchera & Kuchera, 1994b). Commonly TLP techniques are clinically 
indicated as initial treatments for clearing the thoracic duct region to improve lymphatic flow 
and for patients with chronic obstructive pulmonary disease, upper and lower respiratory 
infections, mastitis, or swollen upper extremities or for postsurgical reduction of respiratory 
volume (Ward, 2003). 
 
3.2.1 The Thoracic Lymphatic Pump Without Activation 
Osteopathic textbooks (Kuchera & Kuchera, 1994a, 1995b; Paoletti, 2006; Ward, 2003) and 
research studies (Noll, Degenhardt, Johnson, & Burt, 2008; Noll, Johnson, Baer, & Snider, 
2009) describe two different types of TLP, the TLP Without Activation and the TLP With 
Activation. The TLP Without Activation technique is performed with the patient in the supine 
position and the practitioner standing at the head of the table, placing his or her hands on the 
thoracic wall with the thenar eminence of each hand over the pectoralis muscle just below 
the clavicles (Fig. 2). The fingers are spread and angled towards the patient’s body to evenly 
distribute pressure across the chest wall. The TLP Without Activation consists of a rhythmic 
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pumping action of alternating pressure and release on the patient’s chest at a rate of 110-
120 times/min, while the patient is asked continue breathing as usual (Kuchera & Kuchera, 
1994b; Noll et al., 2009; Ward, 2003). The terminology 'Without Activation' indicates that 
there is no recoil, in this case no sudden release of the hands away from the chest cage, as 
applied during TLP With Activation. Recoil techniques are techniques used in OMT that 
intitiate recoil of certain body tissues by a sudden release of the operator’s hands in relation 
to the patient’s body. The recoil is thought to cause a stimulation of the underlying tissues. 
Osteopathic literature indicates that recoil techniques should not be used in patients with 
certain respiratory conditions that have hyperreactive and or bronchospasmic characteristics  
(e.g. asthma, COPD), as it might further stimulate these characteristics (Kuchera & Kuchera, 
1994a, 1994b; Noll et al., 2008; Ward, 2003). Therefore, TLP Without Activation is the 
primary choice of technique in symptomatic patients but is also commonly used as a 
preventitive and to manage healthy individuals who commonly suffer from respiratory tract 
infections, such as URTI. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Miller's Thoracic Lymphatic Pump (Channel & Mason, 2009)   	  
3.2.2 Mechanisms of TLP in Relation to Salivary Secretory Immunoglobulin A  
The immediate and short-term increase in Sal SIgA after manual intervention such as TLP 
and other types of LPT is most plausibly explained by a combination of different types of 
manual stimulation to the lymphatic system and the ANS. Firstly, the rhythmic pressure of the 
upper chest with TLP could cause an increase in lymphatic flow of the thoracic duct due to 
the pumping mechanism of the technique and due to the decreased resistance to lymphatic 
flow secondary to an increase of mobility of the upper chest. Secondly, the rhythmic 
mobilisation of the upper chest, which connects posteriorly to the upper thoracic spine, is 
also likely to induce an immediate and short-term stimulation of the sympathetic 
preganglionic nerves in the upper thoracic segements of T1-3 that synapse in the superior 
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cervical ganglion with postganglionic neurons that release norepinephrine (Proctor & 
Carpenter, 2007). Norepinephrine binds to ß-adrenergic receptors on the acinar and ductal 
cells of the adrenal glands leading to an increase in salivary gland secretion and a 
synergistic secretion of SIgA. Additionally, this stimulation of the sympathetic nervous system 
might induce an indirect affect on salivary glands and SIgA secretion by vasoconstriction of 
the blood vessels that supply the salivary glands (Proctor & Carpenter, 2007; Ward, 2003b). 
 
3.3 Effect of OMT on the Immune System Within Evidence-Based Practice  
A great number of papers within the osteopathic historical literature claim that OMT, 
especially techniques that involve lymphatic pumping, are efficacious for enhancing immune 
response (Castlio & Ferris-Swift, 1932, 1934; Galbreath, 1929; Smith 1920; Whiting, 1910). 
Unfortunately data from these uncontrolled studies were based on retrospective clinical 
reports. Therefore, it is unclear what population these results can be generelised to. 
Similarly, because patient histories, diagnoses and interventions are not standardised or 
systematically recorded, it is difficult to establish what factors influenced the beneficial 
immune effects. Even some of the studies state promising results, there is often a lack of 
proof of the significance of their results. For example, in 1934, Castlio and Ferris-Swift 
examined the effects of splenic pump on patients with acute infectious disease by taking 
blood as a baseline sample before treatment and at two points following treatment, varying 
from 5 minutes to 2 hours. It was reported that 73% of patients had an increase in total 
leukocyte counts and in 84% of patients had an increase in mature neutrophils, as measured 
by a shift to the right of the Arneth index. There was also an increase in the opsonic index, 
agglutination, and bacteriolytic properties of the serum in patients following treatment (Castlio 
& Ferris-Swift, 1934). Castlio and Ferris-Swift (1934) concluded that the increased leukocyte 
count was a result of contraction of the spleen and expulsion of its contained leukocytes. 
They also believed that the drecreased erythrocyte count was related to an increased 
destruction of red blood cells (Castlio & Ferris-Swift, 1934). Noll, Johnson, & Brooks (2008) 
revisited Castlio and Ferris-Swift's experiment by contemporary nonparametric statistical 
methods and confirmed a modest post-treatment increase in leukocytes, a decrease in 
erythrocytes, a decrease in the Arneth index, and an increase in reticulocytes. However, 
laboratory testing times and the number of splenic compressions used in treatment varied 
independently (Noll et al., 2008). A further limitation is that participants were most likely not 
blinded to the blood draw times, as double-blinding was uncommon during that era and not 
mentioned by the authors. Therefore the key problem is that the lack of blinding and the 
inconsistent study procedure lowers the internal validity of the study and its ability to draw 
conclusions about the effect of lymphatic pump technique.  
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3.4 Thoracic Lymphatic Pump Techniques Within Evidence-Based Practice 
(Table 1) 
There are few studies investigating links between manual therapeutic techniques such as 
TLP and immune health. The TLP has shown to have a positive effect on immune response 
by increased levels of B cells and T cells after vaccination (Jackson et al., 1998; Measel, 
1982) and without antigenic challenges (Measel & Kafity, 1986), as well as an immune 
enhancing effect on health in a post- operative clinical setting (Sleszynski & Kelso, 1993), 
while one controlled study has shown to decrease pulmonary tumours in laboratory rats 
following TLP (Pedrueza, Zhang, Jones, & Hodge, 2010). 
 
Measel (1982) examined TLP and the immune response of male medical students (n=25) 
after vaccination with pneumococcal polysaccharide. Two serological tests, bacterial 
agglutination and passive agglutination were employed to measure the impact on B cell and 
T cell components in the blood. By day 14 the treatment group (n=13), having received twice 
daily TLP, had a statistically greater humoral B cell immune response than the control group 
(n=12). The conclusion was that TLP had a positive effect on B cell and T cell components of 
the human immune system as measured in peripheral blood. In accordance with these 
results, Jackson et al. (1998) demonstrated that TLP and splenic pumping enhanced 
antibody production on hepatitis B vaccination. The experimental subjects (n=20) received 
TLP and splenic pump treatments three times per week for two weeks after each vaccination. 
Subjects were given the vaccinations at 0, 5, and 25 weeks. The control group received the 
vaccinations but no OMT. Resultant serum antibody levels were measured by enzyme 
immunoassay. Fifty percent of the subjects in the treatment group achieved protective 
antibody titers (> or = 10 mlU/mL) by week 13 compared with an average titer of 374 
mlU/mL. Positive antibody responses were measured in 16% of the control group, with 
average titers of 96 mlU/mL. The results were presented as further evidence that TLP and 
LPT enhance immune response. Breithaupt et al. (2001) investigated whether TLP after 
FluShield vaccination would enhance the production of anti-influenza antibodies. Their 
particular interest was in the immune response of elderly populations, as they have an 
increased risk from influenza and achieve lower levels of immunity on influenza vaccination. 
Two healthy test populations, elderly adults and young adults, were randomly divided into 
non-treated controls and TLP-treated subjects. Individuals performing the antibody analysis 
were blinded until assay series were completed. Their results suggest that TLP in 
conjunction with influenza vaccination does not enhance immunisation against influenza in 
otherwise healthy and active populations (Breithaupt et al., 2001) 
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Other studies have investigated the baseline effects of lymphatic pumping by itself without 
antigenic challenges such as vaccines or bacterial antigens. In an uncontrolled study 
abstract, Measel and Kafity (1986) reported that TLP increased total white blood cell (WBC) 
counts, decreased lymphocyte counts and increased the relative percentages of T cells and 
B cells. They reported an average increase by 31.5% from 7460 erythrocytes per µL to 9810 
per µL. The B cell component increased from 5.07% to 9.25% of white blood cell while T cell 
component rose from 73.2% to 80.9%. The TLP may also play a role in recovery from 
surgery. Sleszynski and Kelso (1993) conducted a one-year randomized researcher-blinded 
trial of TLP in patients who had undergone low-risk cholecystectomy. Half of the subjects 
received TLP, while the other half received incentive spirometry. Incentive spirometry is a 
breathing exercise designed to help patients take long, deep breaths in order to decrease the 
chance of developing breathing problems after surgery. Atelectasis, the collapse or closure 
of the lung resulting in reduced or absent gas exchange, occurred in two patients in each 
group. However, patients treated with TLP had earlier recovery and quicker return to 
preoperative values of forced vital capacity than did those treated with incentive spirometry. 
The outcome of this study indicates a possbile immune enhancing effect of TLP on health in 
a post-operative clinical setting. 
 
There is also some evidence from animal studies of the effect of TLP in cancer amelioration. 
Pedrueza, Zhang, Jones, and Hodge (2010) subcutaneously injected laboratory rats with 
tumours that metastasise to the lungs. Following the injection the rats received four minutes 
TLP daily for seven days. A control group received no treatment while a sham group was 
treated with four minutes of light touch. The results demonstrated a 30% reduction in 
pulmonary tumours in the TLP group compared with the control or sham group and there 
was no distribution of tumour cells from the lungs into other tissues following TLP. 
Additionally, TLP produced increased WBC numbers in lungs with tumours, which the 
authors suggested may have played a role in preventing tumors from spreading. However, 
recent research suggests that tumours in animals and humans most likely metastasise 
through the fusion of a white blood cell and a cancer cell to form a genetic hybrid (Lazova et 
al., 2013). There are some questions about the ability to generalise these results to human. It 
is questionable if the operators were able to perform the TLP technique on small subjects like 
rats with the same characteristics as the earlier desribed technique used on humans. Their 
study design and results reflect a rat specific thoracic lymphatic pump technique but should 
not be compared to the osteopathic TLP performed on humans, as for example hand 
positions on subjects must have been different between the two TLP techniques. Further the 
difference in anatomical and physiological properties between rats and humans makes it 
difficult to reflect their results to humans.  
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Table 1: Thoracic Lymphatic Pump Techniques Within Evidence-Based Practice 
 
Author	  (Year)	   Population	  
Characteristics	  
Intervention	   Timeframe	  and	  
Measures	  (per	  
participant)	  
Sample	  and	  Data	  
Analysis	  
Results	  
Breithaupt	  et	  al.	  (2001)	  	   36	  young	  adults	  61	  elderly	  adults	   Randomization	  into:	  	  Experimental	  group	  (n=32	  elderly	  and	  N=18	  young	  adults):	  -­‐	  FluShield	  vaccination	  -­‐	  5	  min.	  TLP	  with	  50	  rpm	  daily	  for	  4	  days	  post-­‐vaccination	  	  Control	  group	  (n=29	  elderly	  and	  n=18	  young	  adults):	  -­‐	  No	  TLP	  	  	  	  
4	  weeks	  	  Blood	  samples	  to	  measure	  positive	  antibodies	  to	  vaccination:	  -­‐	  1	  baseline	  -­‐	  1	  post-­‐	  intervention	  sample	  at	  average	  at	  30	  days	  post-­‐	  vaccination	  	  
Serological	  analysis:	  -­‐	  HIA	  -­‐	  ELISA	  	  Data	  Analysis:	  -­‐	  Mixed	  analysis	  of	  varience	  -­‐	  Chi-­‐square	  tests	  	  
Elderly	  group	  -­‐	  Increase	  in	  antibody	  production	  in	  35%	  of	  TLP	  group	  -­‐	  Increase	  in	  antibody	  production	  on	  vaccination	  in	  30%	  of	  control	  group	  -­‐	  72%	  of	  positive	  responders	  with	  twofold	  or	  fourfold	  antibody	  increase	  	  	  Young	  group:	  -­‐	  Increase	  in	  antibody	  production	  in	  69%	  of	  TLP-­‐group	  -­‐	  Increase	  in	  antibody	  production	  on	  vaccination	  in	  67%	  of	  control	  group	  -­‐	  72%	  of	  positive	  responders	  with	  eightfold	  or	  greater	  antibody	  increase	  	  Jackson	  et	  al.	  (1998)	  	   20	  participants	  	   Treatment	  group	  (n=20):	  -­‐	  Vaccination	  at	  0,	  5,	  25	  weeks	  -­‐	  3	  x	  per	  week	  for	  two	  weeks	  protocol	  of	  OMT	  after	  each	  vaccination:	  -­‐>	  TLP	  -­‐>	  Splenic	  pumping	  	  Control	  group:	  -­‐	  Vaccination	  at	  0,	  5,	  25	  weeks	  -­‐	  No	  OMT	  	  
27	  weeks	  	  Blood	  samples	  to	  measure	  positive	  antibodies	  to	  vaccination	  	  	  
Serological	  analysis	  -­‐	  ELISA	   Treatment	  group:	  -­‐	  50%	  with	  protective	  antibody	  titers	  by	  week	  13	  with	  an	  average	  titer	  of	  374	  mlU/ml	  	  	  Control	  group:	  -­‐	  16%	  with	  	  	  protective	  antibody	  titers	  with	  an	  average	  titer	  of	  96	  mlU/ml	  
Measel	  (1982)	  	   25	  male	  medical	  students	  	   Randomization	  into:	  	  Treatment	  group	  (n=13):	  -­‐	  vaccination	  with	  pneumococcal	  polysaccharide	  -­‐	  5	  min.	  TLP	  	  twice	  daily	  for	  1	  week	  	  Control	  group:	  -­‐	  vaccination	  with	  pneumococcal	  polysaccharide	  -­‐	  No	  TLP	  
14	  days	  	  	  Two	  serological	  tests:	  -­‐	  Bacterial	  agglutination	  -­‐	  Passive	  agglutination	  
-­‐	  Serum	  analysis	  assayed	  by	  agglutination	  	  -­‐	  Split-­‐plot,	  mixed	  model,	  analyses	  of	  varience	  
-­‐	  Increase	  in	  humoral	  B	  cell	  response	  in	  some	  of	  the	  bacterial	  strains	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3.5 Effect of TLP on Salivary SIgA Within Evidence-Based Practice (Table 2) 
In addition to the limited amount of research in the field of TLP within evidence-based 
practice, there are also very few studies investigating and evaluating the immune enhancing 
effects of TLP on Sal SIgA. Two recent studies have investigated the effect of TLP on 
salivary SIgA levels, and concluded positive effects (ES = 2.1 - 3.0) of TLP in isolation or part 
of osteopathic treatment on salivary SIgA (Ehrlenbach, 2011; Saggio et al., 2011). Saggio et 
al. (2011) investigated the impact of OMT on Sal SIgA levels in a stressed population of 
osteopathic medical students. Twenty-five second-year osteopathic medical students were 
randomly assigned to an experimental group (n=12) or a control group (n=13). The 
experimental group received a 20-minute OMT protocol consisting of five minutes of 
occipitoatlantal release, five minutes of rib raising and 10 minutes of TLP. The experimental 
group exhibited a 139% average increase (ES = 2.1) in post-intervention Sal SIgA levels 
which was significantly (p<0.025) greater than the 32% average increase noted in the control 
group. The study by Saggio et al. (2011) demonstrates the positive effect of OMT on Sal 
SIgA levels in a stressed population and the authors suggest possible therapeutic 
preventative and protective effects of OMT on healthy and hospitalised patients, especially 
when experiencing high levels of emotional or physiological stress and when being at risk of 
aquiring URTI. A possible limitation of their study is that participants in the experimental 
group were treated by 1 of 12 operators. Multiple operators increase the chance of inter-rater 
variability by differences in the application of treatment and therefore possible differences in 
treatment outcomes. On the other hand a positive treatment effect with multiple operators 
indicates a positive inter-rater reliability. Inter-rater variabiliy and reliability has not been 
reported by Saggio et al. (2011). While control group participants were asked to rest calmly 
while sitting, experimental group participants were asked to remain seated or supine after the 
20-minute OMT application and rest quietly for one hour, before a second saliva sample was 
collected. Differences in resting position of participants in the experimental group and also 
differences of resting duration in between the groups could have influenced lymphatic flow 
and Sal SIgA levels, resulting in relatively lower levels in the experimental group. 
Unfortunately, the study was unable to determine which OMT technique or combination of 
the three techniques was responsible for the observed increase in Sal SIgA.  
 
Another small cohort study by Ehrlenbach (2011) used a single system research design with 
a modified A-B-C protocol on eight healthy male participants to measure changes in Sal SIgA 
secretion rate in response to a seven-minute treatment of TLP. Baseline measures were 
recorded once daily over 5 days. On Day 5 the single pre- intervention measure was 
immediately followed by the intervention. Two post- intervention measurements, at one-
minute post- treatment and at 10-minute post- treatment were reported. An immediate post- 
	   29	  
treatment short-term increase of Sal SIgA concentration was identified in all eight participants 
and an immediate post- treatment short-term increase of Sal SIgA secretion rate was 
reported in 7 out of 8 participants with a large effect size of 3.0 (Cohen's d formula; p=0.03) 
with an average increase of 136% indicating a strong correlation between TLP and increase 
in immediate post- intervention and short-term Sal SIgA secretion rate. On day 5 participants 
provided the first post-treatment saliva sample directly after TLP. The particpants were then 
guided into an adjacent room and directed to sit quietly while reading a selected textbook 
chapter, before 10 minutes later a second saliva sample was collected. The transfer to an 
adjacent room between the first and second saliva sample on day 5 might have, most likely 
positively, influenced lymphatic flow and Sal SIgA levels. Further the study is limited by 
following a modified A-B-C design, providing only a small number of measures. Baseline 
data were collected at five measurement points, whereas post-treatment changes in Sal 
SIgA were assessed at only two measurement points, immediately and 10 minutes following 
treatment. Therefore, the observed post-treatment changes may have resulted from chance 
variation. The absence of a control group is another potential concern. Because the study 
wasn't controlled, cause and effect links between treatment and the immune changes are 
difficult to establish with certainty.  
 
In addition to limitations arising from study design factors, the mechanism of changes 
observed by Ehrlenbach (2011) are not clear. An effect by the production of new IgA can be 
excluded, as specific production and transportation of SIgA to the site of the saliva collection, 
the salivary glands, would have taken several days. Most likely the increase in Sal SIgA 
levels must have resulted from an increased release of Sal SIgA in the oral cavity.  
 
Apart from the osteopathic reviews that claim efficacy of LPT and TLP in historical clinical 
cases (Amalfitano, 1987; Chikly, 2005; Degenhardt & Kuchera, 1996) and the often claimed 
efficacy of TLP in osteopathic textbooks (Channel & Mason, 2009; Kuchera & Kuchera, 
1994a, 1994b; Ward, 2006) as well as the effect observed on immunological markers in 
humans (Breithaupt et al., 2001; Ehrlenbach, 2011;; Jackson et al., 1998; Measel & Kafity, 
1986; Measel, 1982; Saggio et al., 2011), to date, no studies have investigated the clinical 
outcome of TLP in healthy humans complaining of recurrent URTI and OU, which might be 
indicative of suppressed levels of SIgA. 
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Table 2: Effect of TLP on Salivary SIgA Within Evidence-Based Practice	  
	  
	  
4.0 Conclusion 
Osteopaths have used lymphatic pump techniques for over 100 years and osteopathic 
literature claims their efficacy at increasing lymphatic flow and their importance in the 
treatment and prevention of disease. The results of Saggio et al. (2011) and Ehrlenbach 
(2011) indicate a possible effect of TLP on Sal SIgA. The study outlined in the second part of 
this thesis is linked to that of the 2011 Ehrlenbach study, where a short-term increase in Sal 
SIgA concentration post- treatment was identified in all eight participants. Ehrlenbach's study 
included a five-day baseline with a single saliva sample on each day, as well as only two 
saliva samples pre-intervention. The small number of data points limited the study, as it is 
difficult to identify possible pre-intervention fluctuations of Sal SIgA. However, the data are 
promising enough to follow up on with an increased number of data points to observe and 
discuss possible mechanisms by which TLP affects immediate and short-term Sal SIgA. 
Future studies would need to include a control group and to greatly increase the size of the 
study before any conclusion could be made regarding cause and effect. 
Author	  (Year)	   Population	  
Characteristics	  
Intervention	   Timeframe	  and	  
Measures	  (per	  
participant)	  	  
Sample	  and	  Data	  
Analysis	  
Results	  
Ehrlenbach	  (2011)	  	   8	  healthy	  male	  participants	  -­‐	  21-­‐39	  years	  	   7	  min.	  TLP	   5	  days	  	  -­‐	  Total	  of	  5	  baseline	  saliva	  samples	  (1	  sample	  daily	  for	  5	  consecutive	  days)	  -­‐	  Total	  of	  2	  post-­‐	  intervention	  saliva	  samples	  on	  day	  5	  (1	  min.	  and	  10	  min.	  post-­‐	  intervention)	  	  	  
-­‐	  ELISA	  of	  Sal	  SIgA	  	  -­‐	  Comparison	  of	  group	  means	  (ANOVA)	  -­‐	  Comparison	  of	  pre-­‐	  and	  post-­‐	  intervention	  measures	  (Paired	  t-­‐test)	  -­‐	  Evaluation	  of	  clinical	  significance	  (Cohens	  d	  formula)	  
-­‐	  136%	  average	  increase	  (ES=3.0,	  p=0.03)	  in	  Sal	  SIgA	  
Saggio	  et	  al.	  	  (2011)	  	   25	  	  healthy	  second	  year	  osteopathic	  medial	  students	  :	  -­‐	  12	  men	  -­‐	  13	  women	  -­‐	  18-­‐40	  years	  -­‐	  high	  stress	  levels	  
Randomization	  into:	  	  Experimental	  group	  (n=12):	  -­‐	  20	  min.	  OMT	  protocol:	  -­‐>	  5	  min.	  occipitoatlantal	  release	  -­‐>	  5	  min.	  rib	  raising	  -­‐>	  10	  min.	  TLP	  	  Control	  group:	  -­‐	  20	  min.	  sit	  and	  relax	  
Single	  day	  	  Experimental	  group:	  -­‐	  1	  baseline	  saliva	  sample	  	  -­‐	  1	  saliva	  sample	  60	  min.	  post-­‐	  intervention	  	  Control	  group:	  -­‐	  1	  baseline	  saliva	  sample	  	  -­‐	  1	  saliva	  sample	  60	  min.	  after	  sit	  and	  relax	  	  	  	  
-­‐	  ELISA	  of	  Sal	  SIgA	  	  	  -­‐	  2	  x	  2	  analysis	  of	  variance	  (ANOVA)	  
Experimental	  group:	  -­‐	  139%	  average	  increase	  (ES=	  2.1)	  	  in	  Sal	  SIgA	  levels	  	  Control	  group:	  -­‐	  32%	  average	  increase	  in	  Sal	  SIgA	  levels	  	  	  Interaction	  between	  group	  and	  time:	  -­‐	  p=0.027	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5.0 Thesis Study 
The aim of the research study completed as part of this thesis was to use Ehrlenbach’s 
approach by replicating that study but to include an increased number of baseline and follow-
up data points that assess Sal SIgA variability over the short time-frame that effects were 
reported. In this investigation, on a single day, multiple data points pre-, peri-, and post-
intervention will be collected to get a better understanding of possible fluactuations of Sal 
SIgA pre-intervention and of how the Sal SIgA secretion rate responds to the intervention. 
Furthermore, healthy male adults who report symptoms of recurrent OU and or URTI will be 
selected since these symptoms have been previously associated with relative IgA deficiency. 
It is understood that there are many factors involved in OU/URTI but the presence of 
recurrent episodes of OU/URTI in otherwise healthy individuals suggests a suppressed 
mucosal immunity in that individual. Thus, this study has the potential to provide preliminary 
data regarding the clinical applicability of the TLP technique. This study will focus on how the 
osteopathic TLP technique affects immediate and short-term Sal SIgA secretion rate in four 
healthy male adults complaining of recurrent OU and or URTI. A single case study design 
was deemd most suitable for investigating these aims. 
 
Research and its documentation are crucial factors in the growth and acceptance of any 
profession and the need for experimental research is well recognised within the osteopathic 
profession (Moran, 2005). Group designs, such as randomised controlled trials, are regarded 
as the gold standard of experimental research within evidence based practice, they are often 
inappropriate for preliminary investigations and the logistics of this type of research requires 
sources that are not easily available within the osteopathic profession. Group designs are 
limited in their suitability for certain types of conditions and have been criticised for lacking 
transferability to individuals by representing only an average of the response to any given 
intervention (Sanders, 2003). Immunologic research generally requires large recources 
making single case studies a cost effective solution particularly for the investigation of 
emerging or little researched topics. 
 
This research project will consist of four individual single case studies designed to identify 
the immediate and short-term effect of a single intervention of TLP on Sal SIgA concentration 
(µg/mL) and secretion rates (µg/min) in healthy male subjects complaining of recurrent OU 
and URTI. The presence of URTI and OU will be self-reported identified via a short 
questionnaire and not based on a clinical diagnosis. The intervention will imply a single 
standardised treatment of seven-minute TLP Without Activation. Multiple data points (Fig. 3) 
will be collected on the day of the intervention to get a better understanding of when the 
secretion of Sal SIgA responds to the intervention. Pre- (sample 1-4) and post-intervention 
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(sample 6-9), four saliva samples are collected at 10 minute intervals. The last pre-
intervention sample collection (sample 4) is immediately followed by the intervention. During 
the intervention one saliva sample (sample 5) is collected to identify possible immediate 
effects. The first post-intervention sample collection (sample 6) starts immediately after the 
intervention. Saliva samples will be collected by oral swab and the collection time is limited to 
one minute per sample. Samples will be analysed with a SIgA competitive ELISA kit and 
assays will be analysed with Biotek software Gen5. 
 
 	  	  
  
 
 
 
 
 
 
 
 
Figure 3: Methodology for saliva sample collection.	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Note: The manuscript presented here is intended for submission to the International Journal 
of Osteopathic Medicine (IJOM) but rather than the referencing style specified in the IJOM 
guidelines for authors, the referencing style follows the American Psychological Association 
(“APA”). Elsevier’s initiative ‘Your Paper, Your Way’ (www.elsevier.com/yourpaperyourway) 
now permits manuscripts submitted using other referencing formats and APA was selected 
because it is easier to follow authors’ names in the text and it matches that required for the 
Literature Review.  
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Abstract 
Background:	  
Low levels of salivary SIgA have been associated with upper respiratory tract infection, oral 
ulceration and systemic diseases. Osteopathic Manipulative Treatment has been shown to 
have a positive effect on salivary SIgA levels.	  
Objective: 	  
This single case study aimed to determine changes in salivary SIgA concentration and 
secretion rate in response to a single 7-minute intervention of the osteopathic thoracic 
lymphatic pump in four male subjects who indicated suppressed mucosal immunity identified 
by recurrent upper respiratory tract infection and oral ulceration.	  
Methods:	  
On a single day a total of nine saliva samples were collected per participant via oral swab, 
including four samples pre-, one peri- and four post-intervention. Participant results were 
analysed individually with group statistics reported.	  
Results:	  
At baseline all participants showed suppressed levels of salivary SIgA concentrations with an 
average of 58.03 µg/mL (<79.26 µg/mL). Post-intervention Salivary SIgA concentrations 
increased in three participants [Effect size (ES) = 1.74 - 2.71]. On average salivary SIgA 
concentrations increased to 72.73 µg/mL (25.3%). Salivary SIgA secretion rates showed no 
clear pattern of change (ES = -1.82 to 1.96). On average salivary SIgA secretion rates 
increased from 23.8 µg/min to 24.4 µg/min (5.9%). The mean effect size for salivary SIgA 
secretion rates baseline to post-intervention was d=0.05.	  
Conclusion:	  
This study showed some indication of an overall trend for an increase in salivary SIgA 
concentration. Changes in salivary SIgA secretion rate were inconsistent and the therapeutic 
benefit of the thoracic lymphatic pump in participants with a suppressed mucosal immune 
function remains unclear.	  
 
 
 
 
 
Keywords: Antibody; Aphthous Ulcer, Recurrent; Marker, Biological; Manual Immunomodulatory 
Therapy; Osteopathy; Serology; System, Immune
1.0 Introduction 
Secretory immunoglobulin A (SIgA) is the major immunoglobulin secreted by the mucosal 
system (Wood, 2006) and is found in gastrointestinal fluids, mucosal fluids of the respiratory 
tract, saliva and other mucosal fluids (Wood, 2006). Secretory IgA provides primary 
immunological protection from pathogenic organisms by preventing attachment, penetration, 
replication, and colonization of such organisms on the epithelial surface (Latiff & Kerr, 2007) 
and by interaction with other antibacterial factors in saliva (Jackson et al., 1998). Secretory 
IgA in saliva (salivary SIgA) is a relatively easily measured product of the mucosal immune 
system and is considered to be a major factor in determining the resistance to mucous 
membrane infection (AbouEl-Yazeed, Taha, Elshehaby, & Salem, 2009; Gleeson, Pyne, & 
Callister, 2003).  
  
While salivary SIgA concentrations are not necessarily an indication of health, the literature 
appears to support an association between IgA and health outcomes (Chikly, 2005; Rossen, 
Butler, & Waldman, 1970). Notably, low SIgA has often been associated with infections 
(Gleeson & Pyne, 2000; Gleeson et al., 1999, 2003; Hagewald, Bernimoulin, Kottgen, & 
Kage, 2002; Hanson, Bjokander, & Oxelius, 1983; Klentrou, Cieslak, MacNeil, Vintinner, & 
Plyley, 2002; Moreira, Delgado, Moreira, & Haahtela, 2009; Neville, Gleeson, & Folland, 
2008; Nieman, 1994; Pyne et al., 2000; Teeuw, Bosch, Enno, Veerman, & Amerongen, 
2004), impaired stress response (Saggio, Docimo, Pilc, Norton, & Gilliar, 2011; Volkmann & 
Weekes, 2006), and systemic diseases (Benjamini, Coico, & Sunshine, 2000; Brandtzaeg, 
2007; Hanson et al., 1983; Latiff & Kerr, 2007; Paul, 2003). 
 
The effects of low levels of salivary SIgA in precipitating infection, in particular recurrent 
upper respiratory tract infection (URTI) have been widely studied (Gleeson & Pyne, 2000; 
Gleeson et al., 1995, 1999, 2003; Hagewald et al., 2002; Jemmot & McClelland, 1989; 
Teeuw et al., 2004). Increased incidence of URTI during periods of chronic stress has been 
associated with suppression of salivary SIgA (Jemmot & McClelland, 1989; Volkmann & 
Weekes, 2006). Volkmann and Weekes (2006) assessed differences in stress and anxiety 
markers and upper respiratory tract infection (URTI) prevalence in 34 young adults during a 
low stress (summer holiday) period compared to a high-stress (examination) period. Greater 
stress, anxiety and more prevalent URTI symptoms were observed in the high-stress period, 
compared to low-stress period. A greater difference in URTI prevalence was noted in those 
with SIgA below or cortisol above the median levels, suggesting an impaired immune 
response to stress associated with with low IgA or elevated cortisol. 
 
	   44	  
The increased incidence of URTI has also been associated with exercise-induced low levels 
of salivary SIgA in elite athletes (Gleeson & Pyne, 2000; Gleeson et al., 1999, 2003; Moreira 
et al., 2009; Neville et al., 2008; Nieman, 1994; Pyne et al., 2000). Neville, Gleeson, and 
Folland (2008) examined the relationship between salivary SIgA and URTI in a cohort of elite 
professional yacht racing athletes (n=38) over 50 weeks of training by collecting weekly (38 
hours post-exercise, consistent time of day) unstimulated saliva samples at rest together with 
clinically confirmed URTI, training load and perceived fatigue rating. On a group basis a 
significant (28%, p<0.005) reduction in salivary SIgA occurred during the three weeks prior to 
the URTI episodes and returned to baseline by two weeks after the URTIs. A salivary SIgA 
value lower than 40% of their mean healthy salivary SIgA concentration indicated a one in 
two chance of contracting an URTI within three weeks when an athlete did not have or was 
not recovering from an URTI. Therefore, a decline in salivary SIgA levels have been 
associated with an increased risk of URTI and this increase was directly proportional to the 
magnitude of the decline independent of the absolute salivary SIgA concentration. 
 
Low levels of salivary SIgA have also been linked to an increased incidence of systemic 
diseases. One study investigating immune markers in frequently ill children, aged 2 – 15 
years, with monthly acute (6 – 15 times/year) respiratory disease and combined pathology of 
the upper airway found that 94% of the 270 participants had decreased levels of salivary 
SIgA (Markova & Chuvirov, 2007). In addition, numerous reviews address the relationship 
between SIgA and a variety of oral as well as systemic diseases, including dental caries, 
periodontal disease, mucous membrane diseases, chronic sialadenitis, Sjögren's disease, 
non-Hodgkin's malignant B cell lymphoma, celiac disease, HIV infection and AIDS (AbouEl-
Yazeed et al., 2009; Brandtzaeg, 2007; Paul, 2003). Unfortunately these reviews are 
inconclusive, mainly due to the number of other important variables influencing IgA levels, 
such as impact of flow rate, protein loss during sample handling, difficulties with 
reproducibility and standardization of immunoassays, and uncontrolled admixture of serum-
derived monomeric IgA and IgG to the samples (Brandtzaeg, 2007; Gleeson et al., 1995). 
 
Reports within the osteopathic literature claim that Osteopathic Manipulative Treatment 
(OMT), especially lymphatic pump techniques (LPT) are efficacious for enhancing immune 
response (Chikly, 2005; Smith, 1920; Whiting, 1910). One such technique, the osteopathic 
thoracic lymphatic pump (TLP) is widely used by osteopathic practitioners and is reputed to 
have a beneficial effect on the immune system. The TLP was developed by Miller in 1920 for 
relieving lymphatic stasis, enhancing immune response, and treating infections (Miller, 1923; 
1926). Many osteopaths have claimed this technique improves lymphatic flow by clearing the 
thoracic duct in patients with respiratory infections, mastitis, or swollen upper extremities. 
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They also have used it for postsurgical reduction of respiratory volume (Kuchera & Kuchera, 
1994; Ward, 2003)  
 
Several studies confirm a beneficial immune response from TLP. Measel (1982) reported 
that subjects (n=13) who received TLP had a statistically greater humoral B cell response 
and increased levels of antibodies against pneumococcal polysaccharide two weeks post-
vaccination than a control group (n=12). In accordance with these results, Jackson et al. 
(1998) demonstrated in their study that TLP and splenic pumping enhanced antibody 
production following hepatitis B vaccination. Measel and Kafity (1986) reported that TLP 
increased total white blood cell counts, increased the relative percentages of T cells and B 
cells and decreased lymphocyte counts. 
 
More recently, two studies have investigated the effect of TLP on salivary SIgA levels, and 
concluded positive effects of TLP in isolation or part of osteopathic treatment on SIgA 
(Ehrlenbach, 2011; Saggio et al., 2011). Saggio, Docimo, Pilc, Norton, and Gilliar (2011) 
investigated the impact of OMT, consisting of a combination of three osteopathic techniques 
including TLP, on salivary SIgA levels in a stressed population of 25 osteopathic medical 
students. OMT resulted in a 139% (ES = 2.1) short-term increase in post-intervention 
salivary SIgA levels, compared with a 32% increase in the control group (p=0.027 for 
interaction between group and time). 
The results of Ehrlenbach (2011), in a research project carried out while a Master of 
Osteopathy student at Unitec Institute of Technology, also supported the efficacy of TLP for 
improving salivary SIgA secretion by demonstrating an immediate post-treatment short-term 
increase of salivary SIgA concentration in all eight participants. Further she demonstrated an 
immediate post-treatment short-term increase of salivary SIgA secretion rate (SR) in 7 out of 
8 participants with a large effect size of 3.0 (Cohen's d formula; p=0.03) indicating a strong 
correlation between TLP and increased levels of salivary SIgA secretion rates.  
 
Because of a lack of data points in previous studies, the time-frame of short-term changes in 
salivary SIgA following TLP are unclear. The objective of this single case study design aimed 
to determine changes in salivary SIgA concentration and secretion rate in response to a 
single 7-minute intervention of the osteopathic thoracic lymphatic pump. This investigation 
was conducted in four male subjects who indicated suppressed mucosal immunity identified 
by recurrent upper respiratory tract infection and oral ulceration. This group was selected to 
help maximise any changes that might occur, since these individuals might be more likely to 
have depressed SIgA levels from which a therapeutic benefit might result. 	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2.0 Methods & Materials 
 
2.1 Design 
This report consists of four single case studies with observational measures designed to 
identify how a single standardised treatment protocol of TLP influences immediate and short-
term SIgA concentrations (µg/mL) and secretion rates (µg/min) in saliva of healthy males 
with compromised mucosal immunity identified by recurrent URTI and OU.  
 
The study was conducted in a research facility at an osteopathic student clinic. The research 
protocol was approved by the Unitec Research Ethics Committee (UREC), Unitec Auckland, 
New Zealand, UREC registration number: 2011-1236. 	  
2.2 Participants 
Recruitment of participants was via posters and general announcements to groups based in 
and around the Mt Albert campus of Unitec, Institute of Technology. To be eligible for 
inclusion in the study, participants were healthy, male non-smokers aged between 18 and 40 
years. Individuals with recurrent URTI and or OU were targeted via a questionnaire to 
increase the chance of selecting participants with relatively low levels of salivary SIgA and 
the first eligible males to respond were recruited. The presence of URTI and or OU were self-
reported and not established by clinical diagnosis. Exclusively male subjects were recruited 
to avoid hormonal variations of salivary SIgA during the female menstrual cycle (Albers et al., 
2005). The inclusion criterion of non-smoking was specified to limit the influence that 
smoking has on salivary SIgA concentrations (Norhagen & Engstrom, 1998). 
 
Potential participants were excluded if they met any of the following criteria: 
• a present disease or infection  
• intake of medication that affects the immune system such as antibiotics or steroids 
• Intake of ≥21 standard drinks/week of alcohol) or drug abuse 
• diagnosis of any immunosuppressive syndrome, autoimmune condition including recent 
organ transplant 
• a history of cancer, radiation therapy or chemotherapy in the past three years 
• a contraindication for TLP including rib fractures, osteoporosis, a pacemaker or recent 
thoracic surgery	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2.3 Procedure 
The study protocol was explained to all eligible participants and each participant received a 
hard copy and an emailed information sheet prior to the day of sample collection. 
Participants were asked to refrain from eating, chewing (e.g. gum), drinking and exercising 
for two hours prior to the saliva sample collection, all of which can influence salivary SIgA 
levels. 
 
Data collection was completed in a single day on 28 May 2012. On arrival the study protocol 
was reviewed, verbal and written consent was obtained and all participants completed a 
short questionnaire to determine the presence of factors that may have influenced SIgA 
production 24-hours prior to saliva sampling. Participants wore comfortable loose clothing 
consisting of a pair of shorts and a t-shirt to prevent any tight garment possibly interfering 
with lymphatic flow. Each participant rinsed their mouth with filtered natural water after their 
weight and height were recorded. Participants were reminded to refrain from casual 
conversation or other forms of communication not relevant to safety or to the procedure 
during the saliva collection. Finally each participant was asked to position themself in the 
supine position on one of the two identically adjusted treatment tables. 
 
2.3.1 Saliva Sampling and Analysis 
Prior to the intervention, four saliva samples were collected at 10-minute intervals with the 
last sample immediately followed by the intervention, during which one saliva sample was 
collected to measure immediate effects. Following the intervention, four saliva samples were 
collected at 10-minute intervals with the first sample collected immediately after the 
intervention. Saliva sample collection was conducted as recommended by Salimetrics 
guidelines. Non-stimulated saliva samples were collected via pre-weighed oral swabs made 
of an inert polymer shaped into a 30 x 10 mm cylindrical roll, and immediately stored into 2 
ml snap-lock tubes, which were also pre-weighed and labeled. Oral swabs were placed 
under each participant's tongue for one minute targeting collection of saliva produced mainly 
from the sublingual glands. Each saliva sample was carefully collected and handled with a 
new pair of standard safety gloves to prevent droplet contamination, reweighed and recorded 
a second time before being stored in a snap-lock bag on crushed ice inside a closed cool 
box. After collecting each participant’s set of nine saliva samples, samples were securely 
sealed inside a snap-lock bag, labelled and frozen at the recommended storage temperature 
of -20°C.  
 
One Salimetrics salivary SIgA competitive enzyme-linked immunosorbent assay (ELISA) kit 
was purchased from Stratech Scientific APAC, Australia (Salimetrics Salivary Secretory IgA 
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Indirect Enzyme Immunoassay Kit, Item No.1-1602; 96-Well Kit). Salivary SIgA concentration 
(µg/mL) was determined with the ELISA technique, which uses a horseradish peroxidase 
enzyme conjugated to goat anti-human SIgA as the detecting antibody. Laboratory analysis 
took place at the Unitec School of Health Science laboratory. Laboratory conditions and 
procedures adhered to the recommendations provided with the test kits (Salimetrics salivary 
SIgA ELISA Kit Manual). 
 
Saliva samples were thawed on crushed ice, vortexed and centrifuged at 1500 x g 
(=3000rpm) for 15 minutes. The saliva volume was established by weight, assuming a 
specific gravity of one. All samples were analyzed in duplicate. Assay analysis and 
generation of a standard curve (R² = 0.999) was performed with Gen5 (BioTek Instruments 
Inc., 2002).  
 
2.3.2 Intervention 
The intervention consisted of a single standardised OMT protocol of seven-minute TLP 
without activation. The terminology 'without activation' indicates that there is no initiation of a 
recoil, meaning the operator does not initiate a sudden release of the hands away from the 
chest cage, as is done with different variations of TLP. The TLP was performed by one 
qualified registered New Zealand Osteopath, with the patient supine and the operator 
standing at the head of the table, placing both hands on the anterior thoracic wall with the 
thenar eminence of each hand over the pectoralis muscles just below the clavicles. Fingers 
were spread and angled towards the patient's body to distribute pressure across the chest 
wall. The TLP consisted of a continuous rhythmic pumping action of alternating pressure and 
release on the patient's chest at a rate of about 110-120 repetitions per minute (figure 1). 
The rate was estimated by the operator and was slightly alient depending on the patient's 
own natural recoil. The patient continued breathing at his usual comfortable rate.  
 
 
 
 
 
 
 
 
 
 	  	  	  	  
Figure 1: Intervention of the osteopathic thoracic lymphatic pump (TLP) performed by a qualified registered 
New Zealand Osteopath. 	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2.4 Data Management and Analysis 
Raw data were compiled and manipulated using Microsoft Excel version 2003. 
Immunoglobulin A concentrations and secretion rates at all nine test points were plotted for 
each individual. Visual inspection of graphs for each participant were undertaken using a 
slightly modified Conservative Dual Criteria method (CDC; Cohen, Feinstein, Masuda, & 
Vowles, 2014) with changes in variability assessed from a 2 standard deviation (SD) margin 
plotted either side of the mean of pre-treatment (baseline) measurements (Cashman, 
Mortenson, & Gilbart, 2014). Effect sizes were calculated for each individual using the 
difference between the mean pre-treatment and post-treatment measurements divided by the 
SD of the pre-treatment measurements over the four participants. 
 
 
3.0 Results 
Four men between the ages of 22 and 25 years who fulfilled the inclusion criteria participated 
in the study. All participants were second-year students in the Master of Osteopathy Program 
at the Department of Osteopathy of Unitec Institute of Technology Auckland, New Zealand 
and complained of both recurrent URTI (2-4/year) and OU (2-6/year). Their characteristics 
are shown in Table 1.  	  
The normal range of SIgA concentration is defined by Salimetrics Salivary Research as 
79.26 to 679.50 µg/mL (Salimetrics, 2009). As hypothesized at baseline all four participants 
showed suppressed levels of salivary SIgA concentrations (<79.26 µg/mL), with an average 
of 58.03 µg/mL.  
 
The data for each participant's salivary SIgA concentration and salivary SIgA secretion rates 
pre-, peri- and post-intervention of TLP are shown in Figure 2. Visual inspection of the 
salivary SIgA concentration and secretion rate graphs for each participant shows that only 
two of the three participants had any peri- or post-treatment IgA concentration or secretion 
rates that fell outside a 2 SD range of the mean of their pre-treatment measures. For 
Participant 1, this was a single measurement 10 minutes following treatment. For Participant 
3, measurements during and immediately following treatment were both elevated beyond 2 
SD of measurements taken at baseline. A possible change in trend was noted for Participant 
1, whereby a gradual increase in IgA that occurred prior to treatment appeared to be 
attenuated during and following treatment. 
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Baseline to post-intervention, three of four participants showed increased levels of salivary 
SIgA (Figure 3), with Participant 1 concentrations increasing from a baseline average of 58.3 
µg/mL to 74.1 µg/mL across all post-intervention measures, Participant 2 from 53.5 µg/mL to 
71.9 µg/mL, Participant 3 from 49.7 µg/mL to 74.3 µg/mL (ES=1.74-2.71). Participant 4 
showed no change in concentrations from 70.6 µg/mL at baseline. On average salivary SIgA 
concentrations increased from 58.03 µg/mL before the intervention to 72.73 µg/mL after the 
intervention (25.3%). The mean effect size for salivary SIgA concentrations pre-intervention 
to post-intervention was d=1.62.  
 
When SIgA was expressed as a secretion rate, no clear pattern was evident. Two 
participants increased and two participants decreased their salivary SIgA secretion rates 
baseline to post-intervention (ES=-1.82-1.96). On average salivary SIgA secretion rates 
increased from 23.8 µg/min to 24.4 µg/min (5.9%) The mean effect size for salivary SIgA 
secretion rates pre-intervention to post-intervention was d=0.05. During the intervention 
salivary SIgA concentrations were higher than baseline with an average of 75.19 µg/mL, 
while salivary SIgA secretion rates were lower with an average of 22.34 µg/min. 
 
Table 1: Participant characteristics  
 
 
 
 
 
Participant Age Body
Mass 
Index 
 
Upper 
Respiratory 
Tract 
Infection 
(times/year) 
Oral 
Ulceration 
(times/year) 
Vigorous 
Exercise 
>20min 
(times/week) 
Perceived Stress 
Scale 
(maximum = 40) 
Alcohol 
(standard 
drinks/ 
week) 
1 23 31.5 2 5 1-2 18 3 
2 25 26.3 4 6 3+ 24 20 
3 24 22.5 2 6 1-2 21 13 
4 22 22.1 2 2 3+ 19 5 
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Figure 2: Test points of Individual salivary SIgA concentration [SIgA] (µg/mL) and salivary secretion rates 
SIgA SR (µg/min) in four participants tested before (Test Points 1-4), during (Test Point 5) and after (Test 
Points 6-9) an intervention with the osteopathic thoracic lymphatic pump (P1 = Participant 1, P2 = 
Participant 2, P3 = Participant 3, P4 = Participant 4). The solid horizontal line represents the mean of the 
pre-intervention test points (1-4), with dotted lines showing 2 standard deviations above and below. The 
sloped line shows a fitted linear regression curve of the pre-intervention test points (1-4) extrapolated to 
later test points. 
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Figure 3: Individual data point values of salivary SIgA concentrations [SIgA] (µg/mL) (A) and salivary 
secretion rates SIgA SR (µg/min) (B) in four participants tested before and after osteopathic thoracic 
lymphatic pump. Numbers above bars are effect sizes calculated as the difference between average 
baseline and post-treatment measurements divided by the standard deviation of the pre-treatment 
measurements for all four participants. Dashed line for [SIgA] indicates the lower reference range. 
 
 
 
 
[S
Ig
A
] 
( 4
g
/m
L
)
0
2 0
4 0
6 0
8 0
P re -T LP
P os t-T LP
1 .7 4 2 .0 2 2 .7 1 0
P a rt ic ip a n t N u m b e r
S
Ig
A
 S
R
 (
4
g
/m
in
)
1 2 3 4
0
1 0
2 0
3 0
4 0
5 0
P re -T LP
P os t-T LP
0 .6 9 -0 .6 4 1 .9 6 -1 .8 2
	   53	  
4.0 Discussion 
The primary aim of this single case design was to determine if a single intervention of the 
osteopathic thoracic lymphatic pump (TLP) would cause an immediate or short-term increase 
in salivary SIgA levels. Immediate and short-term effects of TLP on Sal SIgA were 
investigated because it was hypothesized that the neural machnisms underpinning the effect 
would occur during and immediately after treatment. I hypothesized that participants with 
recurrent URTI and OU would have decreased levels of salivary SIgA and that a single 
intervention of TLP would cause a short-term increase in salivary SIgA levels. In this 
preliminary investigation, I have not demonstrated any consistent changes. Two participants, 
One and Three, presented with increased short-term salivary SIgA levels and large effect 
sizes, whereas two participants, Two and Four, did not. Because of the short time-frame for 
observed responses, any changes in salivary SIgA levels are likely to be associated with an 
increased release of salivary SIgA, rather than an increase in IgA production, as the time 
frame was too short in order to produce IgA. 
 
These results do not concur with those of two recent similar studies, which both noted 
increases in salivary SIgA levels with large effect sizes. Saggio et al. (2011) showed OMT 
increased short-term salivary SIgA levels significantly (F, 5.92; p<0.025) in 11 out of 12 
participants with an average increase of 139%. The control group showed an increase in 8 
out of 13 participants with an average increase of 32%. Ehrlenbach (2011) demonstrated an 
immediate post-treatment short-term increase of salivary SIgA concentration in all eight 
participants and an immediate post-treatment short-term increase of salivary SIgA secretion 
rate in 7 out of 8 participants with a large effect size of d=3.0 (Cohen's d formula; p=0.03) 
with an average increase of 136% indicating a strong correlation between TLP and post-
intervention increase of salivary SIgA secretion rate. Increases in the current study are far 
less and less consistent amongst the four participants. Here, large short-term post-treatment 
increases of salivary SIgA concentration of around 25% were observed. Short-term post-
treatment increases of salivary SIgA secretion rate are noted in only two of four participants. 
 
The reasons for differences between past studies and the current findings are unclear. It is 
important to be aware of the impact of salivary flow rate on salivary SIgA, which has 
previously been suggested to explain differences among previous studies (Brandtzaeg, 
2007). In the present study, both salivary SIgA concentrations and secretion rates (corrected 
for changes in salivary flow) have been reported and changes are inconsistent for both 
measures, particularly for secretion rate. In the Ehrlenbach (2011) study, increases were 
consistent for both measure, whereas Saggio et al. (2011) reported only SIgA concentration 
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and not secretion rate. Therefore, differences in outcome measures would not appear to 
explain the differences from past studies in IgA changes noted here. 
 
I observed large effect sizes for Participant One and Three, which are likely to indicate 
important clinical change. The large effect sizes for Participant One and Three suggest there 
may be a high likelihood of a clinical significance and a therapeutic benefit of TLP for some 
individuals. Although SIgA concentration increased for Participant Two following TLP, there 
was no increase when concentration was adjusted for mucosal salivary secretion, and 
salivary SIgA secretion was reduced following TLP. One possible reason why Participants 
Two and Four were different from One and Three might be that Participants One and Three 
participated in vigorous exercise more than three times a week, while Participants Two and 
Four only participated one to two times a week in vigorous exercise. Perhaps TLP is less 
effective in people whose reduced IgA is a consequence of frequent and intense exercise. 
This could be because chronic vigorous exercise may increase the release of salivary SIgA 
and therefore deplete salivary SIgA storage. The build up of IgA in people undergoing 
prolonged intense exercise may be more difficult to alleviate via acute changes in release of 
IgA brought about by a single TLP intervention. No information about the exercise levels in 
either of the previous studies was reported so it is difficult to tell if these patterns emerged 
previously.  
 
Another difference in the design of the present study which might help explain differences in 
results is the timing of outcome measures. In order to improve on the design of Ehrlenbach's 
2011 study, where a small number of data points limited identifying possible fluctuations of 
baseline SIgA in response to TLP, an increased number of baseline, intervention and follow-
up data points were used to assess SIgA variability here. The present study increased the 
data points measuring changes in salivary SIgA up to 30 minutes post-TLP and were 
administered at the same frequency as the baseline measures to allow an equivalent pre- 
and post- intervention comparison of immediate and short-term effects, whereas Ehrlenbach 
limited data points to 10 minutes post-TLP. Saggio et al. (2011) only used two data points, 
one at baseline and one 60 minutes post-TLP.	  
 
This study observed whether participants with recurrent URTI and OU had decreased levels 
of salivary SIgA. Individuals with recurrent URTI and or OU were targeted to increase the 
chance of selecting participants with relatively low levels of salivary SIgA. All four 
participants, who were selected due to recurrent URTI and OU, presented with suppressed 
salivary IgA concentrations. Regardless of the increase in salivary IgA levels, mean post-
treatment salivary SIgA did not attain levels within the normal range for any participant. The 
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suppressed levels of salivary SIgA in all four participants supports the hypothesis that 
individuals with recurrent URTI and OU have decreased levels of salivary SIgA. The 
deliberate selection of individuals with impaired immune function possibly created additional 
variation in design compared with the previous studies of Ehrlenbach (2011) and Saggio et 
al. (2011) and may also be a reason for the differences in results noted. 
Attributing a cause and effect relationship between the treatment and changes in SIgA in this 
study is limited by small sample size and an inability to control for many factors that influence 
SIgA concentration and secretion. Secreted salivary IgA is a relatively easily measured 
output of the immune system. Nevertheless, many variables can influence results, such as 
methodological problems with sample handling, storage and processing, as well as many 
other factors such as stress, infection, diet and exercise. Due to many factors known to 
influence salivary SIgA, it is vital to maximise standardisation of variables. These factors may 
also explain differences noted here compared with previous studies. Saliva secretion might 
have been influenced by the presence of oral swabs as the swabs were fully soaked with 
saliva before the one minute allowed for sample collection elapsed.  
It is still unclear to what extent salivary SIgA can be regarded as an indicator of immune 
health; however, there is growing evidence that increased levels of salivary SIgA may 
represent enhanced mucosal immune function and protection. Moreover, low levels of 
salivary SIgA can reflect some sort of immune suppression.  
 
Despite the common use of TLP by osteopathic practitioners in the treatment of patients with 
immune suppressed conditions, research to validate the therapeutic effect of this technique 
on immune health is limited. Further investigation of the effects of Osteopathic Manipulative 
Treatment techniques on salivary SIgA is therefore warranted. Salivary SIgA as a simple and 
cost-effective immune marker for mucosal immunity is a commonly studied immune marker 
in research projects. Even though there are many methodological problems with sample 
collection, processing and storage, which impede standardisation of normal quantifications in 
humans, there is strong and growing evidence of the association of salivary SIgA with 
various immune health indicators. 
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5.0 Conclusion 
This study was designed as a single case study exploratory investigation to examine the 
feasibility and possible efficacy of a novel approach to managing immune conditions in some 
individuals. There may be some indication of an overall trend for an increase in salivary SIgA 
levels with a single application of TLP that might have been detected with a larger sample 
size or possibly with a greater number of Post-TLP data points. The limited resources allotted 
for this preliminary study did not allow for either.  
Despite two previous studies which reported sizeable effects of TLP on salivary SIgA levels, 
here I have not shown a consistent therapeutic benefit of TLP in participants with a 
suppressed mucosal immune function.  
At this stage, it is unclear why some participants appeared to respond to treatment whilst 
others did not. 
 
 
6.0 Conflict of Interest 
None. 
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                 PARTICIPANT INFORMATION SHEET 
 
 
 
The effect of the osteopathic lymphatic pump technique on  
short-term salivary immunoglobulin A secretion rate  
 
 
 
About this research 
You are invited to take part in a study undertaken as part of a Master of Osteopathy Degree at Unitec 
NZ. This research investigates the effect of a widely used osteopathic technique on antibody levels in 
human saliva. Healthy males between the ages of 18 and 40 years who have experienced recurrent 
infections such as upper respiratory tract infections/colds or mouth ulcers are needed. 
 
 
Participants in this project will be asked to: 
 
• Attend a brief appointment to: 
o Ensure that the inclusion and exclusion criteria are met, and that they are eligible 
for the project.  
o Sign a consent form. 
o Fill out a questionnaire about any previous illnesses or diseases. 
 
• Attend an arranged 120-minute appointment on a single day to answer a questionnaire about 
lifestyle factors such as sleep, exercise, diet and stress levels, and provide  a total of 9 
samples of saliva. Four samples will be collected prior to a 7-minute thoracic lymphatic pump 
treatment on the upper chest, one during the treatment and four after the treatment. You are 
required to abstain from alcohol for 24 hours prior to this appointment and from exercise, food 
or other drinks (except for water) for 1 hour prior to this appointment. 
• Saliva samples are collected with Oral Swab, sterile non-toxic, inert polymer shaped into a 30 
x 10 mm cylinder. The sterile Oral Swab is removed from outer packaging and placed into 
proper mouth location for 1 minute to insure that it is saturated with saliva.  
 
 
The researchers  
The primary researcher is Dominik Blut, post-graduate student in Osteopathy (Master of Osteopathy) 
This project is being supervised by Drs Craig Hilton and Catherine Bacon. 
 
 
Participation and consent 
You have the right to choose not to participate, or to withdraw from this research project at any time 
prior to commencement of data analysis and up to 2 weeks after the date of collection of your 
samples. This can be done by emailing us, phoning us, or telling us when we contact you that you do 
not want to participate. You also have the right to access your own records on request. 
 
Any data collected will be kept in an anonymised format to allow for future re-analysis. This 
data may be re-analysed in future student studies. Appropriate research and ethic approval will be 
sought prior to the use of data collected in this study being made available in additional studies.  
 
If you’re interested in participating please complete a consent form (attached) for this project and 
return it to Dominik Blut. 
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Information and concerns 
If you would like further information about the project or have any concerns, please feel free to contact 
either Dominik Blut or Dr Craig Hilton. 
 
Dominik Blut  dominik.blut@gmail.com 
Dr. Craig Hilton:            chilton@unitec.ac.nz 
 
If you would like further information about the project, please feel free to contact Dominik Blut or, the 
primary researcher, on the details above. 
 
If you have any concerns about the way in which the research is being conducted, you can contact the 
following: 
Health Advocates Trust, Freephone: 0800 555 050, P.O. Box 9983, Newmarket, Auckland. 
Access Ability, Phone: 09 262 5370, Fax: 09 262 5371, P.O. Box 23-725, Papatoetoe, Auckland. 
 
 
Māori participants 
Please be aware that the collected samples of your saliva cannot be returned. 
 
 
Confidentiality 
Your confidentiality and anonymity will be protected in the following ways: 
• Information and data collected from you during this research will be labelled with an 
identification number for the purpose of anonymously comparing your data. 
• All computer records will be accessible solely by passwords held only by the researchers. 
• Any data derived from the research will be anonymous and your identity will be kept 
confidential. 
 
 
A copy of the final report will be available at the Unitec NZ library. You will also be given a summary of 
your own personal data and general findings. Summaries and recommendations may be published in 
research journals. 
 
Finally, we would like to extend our appreciation and thanks to you for your valuable contribution to 
this research. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UREC REGISTRATION NUMBER: 2011-1236 
This study has been approved by the UNITEC Research Ethics Committee from 12.01.12 to 
12.01.13.  If you have any complaints or reservations about the ethical conduct of this research, 
you may contact the Committee through the UREC Secretary (ph: 09 815-4321 ext 7248).  Any 
issues you raise will be treated in confidence and investigated fully, and you will be informed of 
the outcome. 
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            PARTICIPANT CONSENT FORM  
 
 
 
The effect of the osteopathic lymphatic pump technique on  
short-term salivary immunoglobulin A secretion rate  
 
This research project investigates the effect of an osteopathic technique on salivary antibody A levels. The 
research is undertaken by Dominik Blut, a Master of Osteopathy student at Unitec, New Zealand and will be 
supervised by Dr Craig Hilton and Dr Catherine Bacon. 
 
 
Name of Participant:     ________________________________ 
 
I have seen the Participant Information Sheet for people taking part in the project titled ‘The effect of the 
osteopathic lymphatic pump technique on short-term salivary immunoglobulin A secretion rate'. I have had the 
opportunity to read the contents of the information sheet and to discuss the project with Dominik Blut, and I am 
satisfied with the explanations I have been given.  I understand that the anonymised data from the project will be 
held indefinitely for the purposes of future analysis and research.  I understand that taking part in this project is 
voluntary (my choice) and that I may withdraw from the project at any time prior to commencement of data 
analysis and this will in no way affect my access to the services provided by Unitec NZ, or the Unitec Osteopathic 
Clinic. 
 
I understand that I can withdraw from the study if, for any reason, I want to do so. 
• I have had enough time to consider whether I want to take part. 
• I understand that I can withdraw from the study at anytime up until the date of the last data collection session. 
• I understand that my participation in this project is confidential, and no material that could identify me will be 
used in any reports of this project.   
 
I also understand that the collected samples of my saliva will not be returned to me. 
• I acknowledge that any materials collected during the study will be stored securely so that only the 
researchers may access them. I understand that my data collection records will be made available on 
request. I understand that any material collected will made anonymous and kept indefinitely to enable future 
re-analysis. 
 
I know whom to contact if I have any questions or concerns about the project. 
 
The principal researcher for this project is Dominik Blut.   
Contact details: dominik_blut@yahoo.de 
 
Signature:   Date:    /        /      
(participant)         _________________________________  (dd/mm/yyyy)      
 
Project explained by Dominik Blut 
Signature:                 Date:    /        /      
(Dominik Blut)      _________________________________  (dd/mm/yyyy)      
 
The participant should retain a copy of this consent form. 
 
 
UREC REGISTRATION NUMBER: 2011-1236 
This study has been approved by the UNITEC Research Ethics Committee from 12.01.12 to 
12.01.13.  If you have any complaints or reservations about the ethical conduct of this research, 
you may contact the Committee through the UREC Secretary (ph: 09 815-4321 ext 7248).  Any 
issues you raise will be treated in confidence and investigated fully, and you will be informed of 
the outcome. 
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Research Participants Needed 
Do you suffer from recurrent mouth ulcers or upper 
respiratory tract infection/colds?? 
 
We are investigating the effect of an osteopathic 
technique on the levels of a specific antibody in the 
human saliva. 
 
Healthy, non-smoking males with recurrent upper respiratory 
tract infection/colds and/or mouth ulcers aged between 18 and 
40 years are required. 
If you are interested in participating, you will be asked to:  
• Complete a questionnaire about lifestyle factors that may influence 
saliva antibodies such as diet, sleep, stress levels and exercise. This 
will identify whether you are able to participate in the study.  
• If you are available you will be asked to attend our laboratory for 
approximately 120 minutes and provide about 9 saliva samples.  
• During this visit, you will receive a free treatment with a rhythmic 
pumping technique that will be applied to your upper chest by a 
qualified osteopath for a duration of 7 minutes.  
 
 
Contact: 
Dominik Blut Master of Osteopathy student 
Phone:   0220959250 
Email:  dominik_blut@yahoo.de 
 
..or get a participant information sheet by the receptionist!! 
	  
 
 
UREC REGISTRATION NUMBER: 2011-1236 
This study has been approved by the UNITEC Research Ethics Committee from 12.01.12 to 
12.01.13.  If you have any complaints or reservations about the ethical conduct of this research, 
you may contact the Committee through the UREC Secretary (ph: 09 815-4321 ext 7248).  Any 
issues you raise will be treated in confidence and investigated fully, and you will be informed of 
the outcome. 
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Appendix C - Questionnaires 
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Study Enrolment Questionnaire 
Name:     
Address :                            
Date of birth:                         Ethnicity:                                                        
Phone number:     Email:                             
Male ¨     Female ¨     Smoker: ¨ yes    ¨ no 
Weight:                                   Height: 
 
1. Please list below any medications that you are presently taking: 
........................................................................................................  
2. Do you suffer from any medical condition?  
¨ yes   ¨  no 
3. Are you presently receiving any medical treatment?  
¨ yes   ¨  no 
4. Do you have any allergies?  
¨ yes   ¨  no 
5. Do you suffer from common viral or bacterial infection, such as upper respiratory infections, colds?  
¨ yes    ¨ no  If yes, please state how often per year:   ____x/per year 
3. Do you presently suffer from any viral or bacterial infection?  
¨ yes    ¨ no 
6. Do you suffer from common mouth ulcers/sores, tooth or gum infections? 
¨ yes    ¨ no  If yes, please state how often per year:   ____x/per year 
7. Do you presently have any mouth ulcers, tooth or gum infections?  
¨ yes    ¨ no 
8. Did you recently have any dental extractions or dental surgery?  
¨ yes    ¨ no 
9. Have you ever been diagnosed with any infectious disease such as AIDS, Hepatitis or Syphilis? 
¨  yes   ¨ no  
10. Is there a history of haemophilia in your family?   
¨ yes     ¨ no 
11. Have you ever been diagnosed with IgA deficiency?  
¨ yes     ¨ no 
12. Have you ever been diagnosed with an autoimmune disorder?  
¨ yes     ¨ no 
13. Have you ever been diagnosed with any form of cancer, sickle cell disease, aneurysms, cardiac 
failure or varicose veins?  
¨ yes    ¨ no 
14. Did you recently (within last 2 weeks) return from a long distance flight?  
¨ yes    ¨ no 
15. Do you ever experience pain in your legs during exercising?    
¨ yes    ¨ no 
16. Have you ever been diagnosed with deep vein thrombosis?     
¨ yes    ¨ no 
17. Did you recently undergo any procedure or surgery in the upper body area?  
¨ yes    ¨ no 
18. Do you suffer from any condition/illness for which you are currently receiving treatment? 
¨ yes    ¨ no 
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The following questions aim to establish lifestyle factors that are known to 
have an influence on salivary antibodies.  
 
Please answer as indicated. 
 
 
Listed below are a series of statements about people’s exercise habits. Please circle the number that 
reflects how often you could make the following statements:  
1 – NEVER              2 – SOMETIMES              3 – USUALLY              4 – ALWAYS 
 
1.       I engage in physical exercise on a daily basis. 
1    2     3    4  
2.       I engage in one/more of the following forms of exercise: walking, jogging/running or weight 
lifting. 
  1    2     3    4  
3.       I exercise more than three days per week. 
  1    2     3    4  
4.  How often do you take part in vigorous exercise (sufficient to make you slightly breathless and  
makes your heart beat faster) which lasts for 20 minutes or more? (please circle) 
A     occasionally or never 
B     once or twice a week 
C     three times a week or more 
 
 
 
Listed below are some questions regarding your diet. Please answer as indicated. 
 
1. Are you currently dieting to reduce your weight?  
¨yes    ¨ no 
2. Do you regularly take any dietary supplements?           
¨yes    ¨ no 
If yes, please list them here: 
 
................................................................................ 
3. How many standard drinks of alcohol do you drink per week? 
 
.............................................. 
 
Examples for standard drinks:  
• 1 small bottle of beer (330ml) with 4% Alc.  ≈ 1 standard drink 
• 1 small bottle of beer (330ml) with 5% Alc.  ≈ 1,3 standard drinks 
 
• 1 glass of red or white wine (100ml) with 14% Alc. ≈ 1 standard drink 
• 1 bottle of red or white wine (750ml) with 14% Alc. ≈ 8 standard drinks 
 
• 1 shot of spirits (30ml) with 37,5% Alc.  ≈ 1 standard drink 
• 1 bottle of spirits (500ml) with 37,5% Alc.  ≈ 16 standard drinks 
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 Date:      ______ / ______ / ________   
 (dd/mm/yyyy) 
  
  
 Signature:     ______________________________                                                                
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Pre- Sample Collection Questionnaire 
 
 
Date:        ____________________________________________________       
 
Name:      ____________________________________________________ 
 
 
 
 
This questionnaire aims to determine factors that may have influenced your salivary 
antibody levels in the past 24 hours.  
Please answer the following questions as indicated. 
 
 
1. Did you engage in any exercise in the last 24 hours (sufficient to make you slightly      
 breathless and make your heart beat faster for more than 20 minutes?    
 Yes  ¨  No  ¨   
    If you answered yes, please indicate time: _________________________________________ 
 
 
2. Did you drink any alcohol or coffee in the last 24 hours?                      
    Yes  ¨  No  ¨   
    If you answered yes, please indicate amount and time _______________________________ 
 
 
3. Did you have any food, drink (other than water) in the last hour?       
    Yes  ¨  No  ¨   
    If you answered yes, please indicate type and amount: ______________________________ 
 
 
 4. How many hours do you usually sleep per night? __________________________________ 
 
 
 5. How many hours did you sleep last night? ________________________________________ 
   
 
 6. How would you rate your average stress level in the last 24 hours on a scale from 0 to 10?  
     (please circle) 
 
      1    2     3    4     5     6      7     8     9    10   (1=minimal, 10=maximal) 
 
 7. How would you rate your stress level at this moment on a scale from 0 to 10? (please circle)  
 
      1    2     3    4     5     6      7     8     9    10   (1=minimal, 10=maximal) 
 
 8. Did you have any symptoms of a bacterial or viral infection in the past 24 hours?  
      (temperature, sore throat, cough, runny nose) 
      Yes  ¨  No  ¨   
 
 
 
Signature:         _________________________________                                                     	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Appendix D - Sample Collection Sheets 
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Participant Nr.:  
 
Arrival Time: 
 
 
Rinse Mouth:  
 
Consent Form:  
 
Questionnaire:  
 
Weight/Size:  
 
 
Sample Oral Swab Weight 
Pre 
Oral Swab Weight 
Post 
S1: 
 
  
S2: 
 
  
S3: 
 
  
S4: 
 
  
I N T E R V E N T I O N 
S5: 
 
  
I N T E R V E N T I O N 
S6: 
 
  
S7: 
 
  
S8: 
 
  
S9: 
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Appendix E - Plate Layout & Data Matrix 
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   1 2 3 4 5 6 7 8 9 10 11 12 
A 
STD1 STD1 HCTL HCTL SPL7 SPL7 SPL15 SPL15 SPL23 SPL23 SPL31 SPL31 
600 600                     
Standards Standards High Control 
High 
Control                 
B 
STD2 STD2 LCTL LCTL SPL8 SPL8 SPL16 SPL16 SPL24 SPL24 SPL32 SPL32 
200 200                     
Standards Standards Low Control 
Low 
Control                 
C 
STD3 STD3 SPL1 SPL1 SPL9 SPL9 SPL17 SPL17 SPL25 SPL25 SPL33 SPL33 
66.7 66.7                     
Standards Standards                     
D 
STD4 STD4 SPL2 SPL2 SPL10 SPL10 SPL18 SPL18 SPL26 SPL26 SPL34 SPL34 
22.2 22.2                     
Standards Standards                     
E 
STD5 STD5 SPL3 SPL3 SPL11 SPL11 SPL19 SPL19 SPL27 SPL27 SPL35 SPL35 
7.4 7.4                     
Standards Standards                     
F 
STD6 STD6 SPL4 SPL4 SPL12 SPL12 SPL20 SPL20 SPL28 SPL28 SPL36 SPL36 
2.5 2.5                     
Standards Standards                     
G 
Bo Bo SPL5 SPL5 SPL13 SPL13 SPL21 SPL21 SPL29 SPL29 SPL36 SPL36 
                        
Zero Zero                     
H 
NSB NSB SPL6 SPL6 SPL14 SPL14 SPL22 SPL22 SPL30 SPL30 SPL19 SPL19 
                        
Nonspecific 
Binding 
Nonspecific 
Binding                     	  
 
 
 	  
	  	   1 2 3 4 5 6 7 8 9 10 11 12 
A 0.245 0.244 0.25 0.257 0.678 0.691 0.84 0.844 0.758 0.777 0.943 0.925 
B 0.379 0.386 0.627 0.621 1.054 1.064 0.915 1.007 0.77 0.787 1.017 0.944 
C 0.566 0.572 1.064 1.045 0.994 1.011 1.054 1.064 1.019 0.992 0.849 0.931 
D 0.828 0.826 0.907 0.917 0.772 0.769 0.949 0.965 0.887 0.982 0.992 0.935 
E 1.138 1.136 0.934 0.952 1.128 1.118 0.951 1.178 1.133 1.061 0.52 0.506 
F 1.232 1.234 0.956 0.752 0.958 0.974 1.024 1.001 0.936 0.933 1 1.037 
G 1.314 1.35 0.985 1.017 1.073 1.109 0.955 0.958 0.985 1.007 1.007 0.937 
H 0.058 0.056 1.099 1.097 0.907 0.896 1.15 1.134 0.89 0.896 0.973 1.023 	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Appendix F - Raw Data & Standard Curve 	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Well ID Name Well Conc/Dil 450 Count Mean Std Dev CV (%) 
NSB Nonspecific Binding H1   0.058 2 0.057 0.001 2.481 
    H2   0.056         
HCTL High Control A3   0.25 2 0.254 0.005 1.953 
    A4   0.257         
LCTL Low Control B3   0.627 2 0.624 0.004 0.68 
    B4   0.621         
Bo Zero G1   1.314 2 1.332 0.025 1.911 
    G2   1.35         
SPL1   C3   1.064 2 1.055 0.013 1.274 
    C4   1.045         
SPL2   D3   0.907 2 0.912 0.007 0.775 
    D4   0.917         
SPL3   E3   0.934 2 0.943 0.013 1.35 
    E4   0.952         
SPL4   F3   0.956 2 0.854 0.144 16.891 
    F4   0.752         
SPL5   G3   0.985 2 1.001 0.023 2.26 
    G4   1.017         
SPL6   H3   1.099 2 1.098 0.001 0.129 
    H4   1.097         
SPL7   A5   0.678 2 0.685 0.009 1.343 
    A6   0.691         
SPL8   B5   1.054 2 1.059 0.007 0.668 
    B6   1.064         
SPL9   C5   0.994 2 1.002 0.012 1.199 
    C6   1.011         
SPL10   D5   0.772 2 0.77 0.002 0.275 
    D6   0.769         
SPL11   E5   1.128 2 1.123 0.007 0.63 
    E6   1.118         
SPL12   F5   0.958 2 0.966 0.011 1.171 
    F6   0.974         
SPL13   G5   1.073 2 1.091 0.025 2.333 
    G6   1.109         
SPL14   H5   0.907 2 0.901 0.008 0.863 
    H6   0.896         
SPL15   A7   0.84 2 0.842 0.003 0.336 
    A8   0.844         
SPL16   B7   0.915 2 0.961 0.065 6.769 
    B8   1.007         
SPL17   C7   1.054 2 1.059 0.007 0.668 
    C8   1.064         
SPL18   D7   0.949 2 0.957 0.011 1.182 
    D8   0.965         
SPL19   E7   0.951 2 1.065 0.161 15.079 
    E8   1.178         
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SPL20   F7   1.024 2 1.013 0.016 1.606 
    F8   1.001         
SPL21   G7   0.955 2 0.957 0.002 0.222 
    G8   0.958         
SPL22   H7   1.15 2 1.142 0.011 0.991 
    H8   1.134         
SPL23   A9   0.758 2 0.768 0.013 1.75 
    A10   0.777         
SPL24   B9   0.77 2 0.778 0.012 1.544 
    B10   0.787         
SPL25   C9   1.019 2 1.006 0.019 1.899 
    C10   0.992         
SPL26   D9   0.887 2 0.935 0.067 7.188 
    D10   0.982         
SPL27   E9   1.133 2 1.097 0.051 4.641 
    E10   1.061         
SPL28   F9   0.936 2 0.935 0.002 0.227 
    F10   0.933         
SPL29   G9   0.985 2 0.996 0.016 1.562 
    G10   1.007         
SPL30   H9   0.89 2 0.893 0.004 0.475 
    H10   0.896         
SPL31   A11   0.943 2 0.934 0.013 1.363 
    A12   0.925         
SPL32   B11   1.017 2 0.981 0.052 5.265 
    B12   0.944         
SPL33   C11   0.849 2 0.89 0.058 6.515 
    C12   0.931         
SPL34   D11   0.992 2 0.964 0.04 4.183 
    D12   0.935         
SPL35   E11   0.52 2 0.513 0.01 1.93 
    E12   0.506         
SPL36   F11   1 2 1.019 0.026 2.569 
    F12   1.037         
SPL37   G11   1.007 2 0.972 0.049 5.092 
    G12   0.937         
SPL38   H11   0.973 2 0.998 0.035 3.543 
    H12   1.023         
STD1 Standards A1 600 0.245 2 0.245 0.001 0.289 
    A2 600 0.244         
STD2 Standards B1 200 0.379 2 0.383 0.005 1.294 
    B2 200 0.386         
STD3 Standards C1 66.7 0.566 2 0.569 0.004 0.746 
    C2 66.7 0.572         
STD4 Standards D1 22.2 0.828 2 0.827 0.001 0.171 
    D2 22.2 0.826         
STD5 Standards E1 7.4 1.138 2 1.137 0.001 0.124 
    E2 7.4 1.136         
STD6 Standards F1 2.5 1.232 2 1.233 0.001 0.115 
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    F2 2.5 1.234         
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Appendix G - Figures  
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Individual data point values of salivary SIgA concentrations [IgA] (µg/mL) in four participants tested 
before (test points 1-4), during (test point 5) and after (test points 6-9) an intervention with the 
osteopathic thoracic lymphatic pump. 	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Individual data point values of mean salivary SIgA concentrations [IgA] (µg/mL) of four participants 
before (MeanPre) and after (MeanPost) an intervention with the osteopathic thoracic lymphatic pump. 	  	  	  	  
1	   2	   3	   4	   5	   6	   7	   8	  Participant	  1	   36.8	   60.4	   54.3	   81.7	   31.6	   146.6	   36.2	   44.1	  Participant	  2	   102.6	   29.0	   50.1	   32.4	   98.1	   65.8	   36.2	   51.7	  Participant	  3	   57.3	   42.6	   66.0	   32.9	   126.6	   55.7	   72.2	   40.7	  Participant	  4	   71.2	   57.5	   82.2	   71.4	   84.0	   64.7	   412.6	   63.0	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Appendix H - Journal Publication Information	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